

Antoni BayÀ©s-GenÀ-s

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3853323/publications.pdf>

Version: 2024-02-01

725
papers

27,544
citations

10373

72
h-index

11303

136
g-index

783
all docs

783
docs citations

783
times ranked

22751
citing authors

#	ARTICLE	IF	CITATIONS
1	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. <i>European Heart Journal</i> , 2021, 42, 3599-3726.	1.0	5,558
2	NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients. <i>European Heart Journal</i> , 2006, 27, 330-337.	1.0	978
3	Pregnancy-Associated Plasma Protein A as a Marker of Acute Coronary Syndromes. <i>New England Journal of Medicine</i> , 2001, 345, 1022-1029.	13.9	509
4	Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations. <i>European Journal of Heart Failure</i> , 2019, 21, 715-731.	2.9	446
5	A critical role for elastin signaling in vascular morphogenesis and disease. <i>Development (Cambridge)</i> , 2003, 130, 411-423.	1.2	400
6	The Insulin-Like Growth Factor Axis. <i>Circulation Research</i> , 2000, 86, 125-130.	2.0	392
7	Atrial Fibrillation Is Associated With Increased Spontaneous Calcium Release From the Sarcoplasmic Reticulum in Human Atrial Myocytes. <i>Circulation</i> , 2004, 110, 1358-1363.	1.6	301
8	Interatrial blocks. A separate entity from left atrial enlargement: a consensus report. <i>Journal of Electrocardiology</i> , 2012, 45, 445-451.	0.4	292
9	Extracellular vesicle isolation methods: rising impact of size-exclusion chromatography. <i>Cellular and Molecular Life Sciences</i> , 2019, 76, 2369-2382.	2.4	224
10	Head-to-Head Comparison of 2 Myocardial Fibrosis Biomarkers for Long-Term Heart Failure Risk Stratification. <i>Journal of the American College of Cardiology</i> , 2014, 63, 158-166.	1.2	222
11	Soluble ST2 for Predicting Sudden Cardiac Death in Patients With Chronic Heart Failure and Left Ventricular Systolic Dysfunction. <i>Journal of the American College of Cardiology</i> , 2009, 54, 2174-2179.	1.2	205
12	A Test in Context: Nephilysin. <i>Journal of the American College of Cardiology</i> , 2016, 68, 639-653.	1.2	197
13	Genetic Variants Associated With Cancer Therapy-Induced Cardiomyopathy. <i>Circulation</i> , 2019, 140, 31-41.	1.6	195
14	The MUSIC Risk score: a simple method for predicting mortality in ambulatory patients with chronic heart failure. <i>European Heart Journal</i> , 2009, 30, 1088-1096.	1.0	194
15	Self-care of heart failure patients: practical management recommendations from the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2021, 23, 157-174.	2.9	181
16	Atrial Failure as a Clinical Entity. <i>Journal of the American College of Cardiology</i> , 2020, 75, 222-232.	1.2	174
17	Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Association-European Society of Cardiology. <i>European Heart Journal</i> , 2018, 39, 4243-4254.	1.0	171
18	Acute heart failure congestion and perfusion status: impact of the clinical classification on in-hospital and long-term outcomes; insights from the ESC-EORP-HFA Heart Failure Long-Term Registry. <i>European Journal of Heart Failure</i> , 2019, 21, 1338-1352.	2.9	170

#	ARTICLE	IF	CITATIONS
19	N-terminal probrain natriuretic peptide (NT-proBNP) in the emergency diagnosis and in-hospital monitoring of patients with dyspnoea and ventricular dysfunction. <i>European Journal of Heart Failure</i> , 2004, 6, 301-308.	2.9	169
20	Sildenafil for improving outcomes in patients with corrected valvular heart disease and persistent pulmonary hypertension: a multicenter, double-blind, randomized clinical trial. <i>European Heart Journal</i> , 2018, 39, 1255-1264.	1.0	166
21	Prognostic Value of High-Sensitivity Troponin T in Chronic Heart Failure. <i>Circulation</i> , 2018, 137, 286-297.	1.6	157
22	Nanosized UCMSC-derived extracellular vesicles but not conditioned medium exclusively inhibit the inflammatory response of stimulated T cells: implications for nanomedicine. <i>Theranostics</i> , 2017, 7, 270-284.	4.6	155
23	Renal Dysfunction in Patients With Heart Failure With Preserved Versus Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2012, 5, 309-314.	1.6	152
24	Recovered heart failure with reduced ejection fraction and outcomes: a prospective study. <i>European Journal of Heart Failure</i> , 2017, 19, 1615-1623.	2.9	149
25	Increased stem cell proliferation in atherosclerosis accelerates clonal hematopoiesis. <i>Cell</i> , 2021, 184, 1348-1361.e22.	13.5	149
26	Cardiopietic cell therapy for advanced ischemic heart failure: results at 39 weeks of the prospective, randomized, double blind, sham-controlled CHART-1 clinical trial. <i>European Heart Journal</i> , 2017, 38, ehw543.	1.0	148
27	New Insights into Elastin and Vascular Disease. <i>Trends in Cardiovascular Medicine</i> , 2003, 13, 176-181.	2.3	145
28	Pretreatment with corticosteroids attenuates the efficacy of colchicine in preventing recurrent pericarditis: a multi-centre all-case analysis. <i>European Heart Journal</i> , 2005, 26, 723-727.	1.0	140
29	Impact of Frailty on Mortality and Hospitalization in Chronic Heart Failure: A Systematic Review and Meta-Analysis. <i>Journal of the American Heart Association</i> , 2018, 7, e008251.	1.6	140
30	Soluble Nephrylysin Is Predictive of Cardiovascular Death and Heart Failure Hospitalization in Heart Failure Patients. <i>Journal of the American College of Cardiology</i> , 2015, 65, 657-665.	1.2	137
31	Insulin-Like Growth Factor Binding Protein-4 Protease Produced by Smooth Muscle Cells Increases in the Coronary Artery After Angioplasty. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2001, 21, 335-341.	1.1	136
32	Amino-Terminal Pro-Brain Natriuretic Peptide, Renal Function, and Outcomes in Acute Heart Failure. <i>Journal of the American College of Cardiology</i> , 2006, 48, 1621-1627.	1.2	136
33	Global position paper on cardiovascular regenerative medicine. <i>European Heart Journal</i> , 2017, 38, 2532-2546.	1.0	133
34	Dynamic Trajectories of Left Ventricular Ejection Fraction in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2018, 72, 591-601.	1.2	132
35	Combined use of high-sensitivity ST2 and NTproBNP to improve the prediction of death in heart failure. <i>European Journal of Heart Failure</i> , 2012, 14, 32-38.	2.9	130
36	Prognostic Value of Soluble Suppression of Tumorigenicity-2 in Chronic Heart Failure. <i>JACC: Heart Failure</i> , 2017, 5, 280-286.	1.9	127

#	ARTICLE	IF	CITATIONS
37	sST2 Predicts Outcome in Chronic Heart Failure Beyond NT-proBNP and High-Sensitivity Troponin T. <i>Journal of the American College of Cardiology</i> , 2018, 72, 2309-2320.	1.2	126
38	Effect of Body Mass Index on Diagnostic and Prognostic Usefulness of Amino-Terminal Pro-Brain Natriuretic Peptide in Patients With Acute Dyspnea. <i>Archives of Internal Medicine</i> , 2007, 167, 400.	4.3	125
39	Myocardial Remodeling in Hypertension. <i>Hypertension</i> , 2018, 72, 549-558.	1.3	123
40	NT-proBNP (N-Terminal pro-B-Type Natriuretic Peptide)-Guided Therapy in Acute Decompensated Heart Failure. <i>Circulation</i> , 2018, 137, 1671-1683.	1.6	122
41	Estimated Glomerular Filtration Rate and Prognosis in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2012, 59, 1709-1715.	1.2	121
42	Long-Term Potassium Monitoring and Dynamics in Heart Failure and Risk of Mortality. <i>Circulation</i> , 2018, 137, 1320-1330.	1.6	121
43	Clonal Hematopoiesis and Risk of Progression of Heart Failure With Reduced Left Ventricular Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1747-1759.	1.2	111
44	Clinical and Prognostic Significance of sST2 in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2019, 74, 2193-2203.	1.2	110
45	A novel discharge risk model for patients hospitalised for acute decompensated heart failure incorporating N-terminal pro-B-type natriuretic peptide levels: a European collaboration on Acute decompensated Heart Failure: The ESCORP-HF Score. <i>Heart</i> , 2014, 100, 115-125.	1.2	106
46	D-Dimer is an early diagnostic marker of coronary ischemia in patients with chest pain. <i>American Heart Journal</i> , 2000, 140, 379-384.	1.2	105
47	Human progenitor cells derived from cardiac adipose tissue ameliorate myocardial infarction in rodents. <i>Journal of Molecular and Cellular Cardiology</i> , 2010, 49, 771-780.	0.9	104
48	Meta-Analysis of Soluble Suppression of Tumor Necrosis Factor-2 and Prognosis in Acute Heart Failure. <i>JACC: Heart Failure</i> , 2017, 5, 287-296.	1.9	104
49	Usefulness of Intermediate Amino-Terminal Pro-Brain Natriuretic Peptide Concentrations for Diagnosis and Prognosis of Acute Heart Failure. <i>American Journal of Cardiology</i> , 2006, 98, 386-390.	0.7	103
50	Health-Related Quality of Life and Mortality in Heart Failure: The Global Congestive Heart Failure Study of 23 000 Patients From 40 Countries. <i>Circulation</i> , 2021, 143, 2129-2142.	1.6	101
51	Effect of aging on the pluripotential capacity of human CD105+mesenchymal stem cells. <i>European Journal of Heart Failure</i> , 2006, 8, 555-563.	2.9	99
52	Development of a Novel Heart Failure Risk Tool: The Barcelona Bio-Heart Failure Risk Calculator (BCN) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	1.3	97
53	Effect of β -Blocker Withdrawal on Functional Capacity in Heart Failure and Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2021, 78, 2042-2056.	1.2	97
54	Mechanisms of action of sacubitril/valsartan on cardiac remodeling: a systems biology approach. <i>Npj Systems Biology and Applications</i> , 2017, 3, 12.	1.4	96

#	ARTICLE	IF	CITATIONS
55	Interatrial block and atrial arrhythmias in centenarians: Prevalence, associations, and clinical implications. <i>Heart Rhythm</i> , 2016, 13, 645-651.	0.3	93
56	Inappropriate doses of direct oral anticoagulants in real-world clinical practice: prevalence and associated factors. A subanalysis of the FANTASIA Registry. <i>Europace</i> , 2018, 20, 1577-1583.	0.7	93
57	Biomarker-assist score for reverse remodeling prediction in heart failure: The ST2-R2 score. <i>International Journal of Cardiology</i> , 2015, 184, 337-343.	0.8	92
58	Common mechanistic pathways in cancer and heart failure. A scientific roadmap on behalf of the <scp>Translational Research Committee</scp> of the <scp>Heart Failure Association</scp> (<scp>HFA</scp>) of the <scp>European Society of Cardiology</scp> (<scp>ESC</scp>). <i>European Journal of Heart Failure</i> , 2020, 22, 2272-2289.	2.9	92
59	Value of electrocardiographic algorithm based on ST-segments and downslopes of ST in assessment of a culprit artery in evolving inferior wall acute myocardial infarction. <i>American Journal of Cardiology</i> , 2004, 94, 709-714.	0.7	87
60	Soluble ST2 Serum Concentration and Renal Function in Heart Failure. <i>Journal of Cardiac Failure</i> , 2013, 19, 768-775.	0.7	87
61	The role and potential of umbilical cord blood in an era of new therapies: a review. <i>Stem Cell Research and Therapy</i> , 2015, 6, 123.	2.4	85
62	Effect of a Strategy of Comprehensive Vasodilation vs Usual Care on Mortality and Heart Failure Rehospitalization Among Patients With Acute Heart Failure. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 2292.	3.8	85
63	New-onset atrial fibrillation after cavotricuspid isthmus ablation: identification of advanced interatrial block is key. <i>Europace</i> , 2015, 17, 1289-1293.	0.7	84
64	Unravelling the interplay between hyperkalaemia, renin-angiotensin-aldosterone inhibitor use and clinical outcomes. Data from 9222 chronic heart failure patients of the ESC-HFA-EORP Heart Failure Long-Term Registry. <i>European Journal of Heart Failure</i> , 2020, 22, 1378-1389.	2.9	83
65	Prognosis and NT-proBNP in heart failure patients with preserved versus reduced ejection fraction. <i>Heart</i> , 2019, 105, heartjnl-2018-314173.	1.2	81
66	Sex- and age-related differences in the management and outcomes of chronic heart failure: an analysis of patients from the ESC HFA EORP Heart Failure Long-Term Registry. <i>European Journal of Heart Failure</i> , 2020, 22, 92-102.	2.9	81
67	NT-ProBNP Reduction Percentage During Admission for Acutely Decompensated Heart Failure Predicts Long-Term Cardiovascular Mortality. <i>Journal of Cardiac Failure</i> , 2005, 11, S3-S8.	0.7	80
68	Vascular dysfunction in idiopathic dilated cardiomyopathy. <i>Nature Reviews Cardiology</i> , 2009, 6, 590-598.	6.1	79
69	Epigenetic Biomarkers in Cardiovascular Diseases. <i>Frontiers in Genetics</i> , 2019, 10, 950.	1.1	79
70	Identification of Male Cardiomyocytes of Extracardiac Origin in the Hearts of Women with Male Progeny: Male Fetal Cell Microchimerism of the Heart. <i>Journal of Heart and Lung Transplantation</i> , 2005, 24, 2179-2183.	0.3	78
71	Effects of Adipose Tissue-Derived Stem Cell Therapy After Myocardial Infarction: Impact of the Route of Administration. <i>Journal of Cardiac Failure</i> , 2010, 16, 357-366.	0.7	77
72	Macrophages, myofibroblasts and neointimal hyperplasia after coronary artery injury and repair. <i>Atherosclerosis</i> , 2002, 163, 89-98.	0.4	76

#	ARTICLE	IF	CITATIONS
73	Negative Clinical Outcomes Associated With Drug-Related Problems in Heart Failure (HF) Outpatients: Impact of a Pharmacist in a Multidisciplinary HF Clinic. <i>Journal of Cardiac Failure</i> , 2011, 17, 217-223.	0.7	76
74	Usefulness of clinical and NT-proBNP monitoring for prognostic guidance in destabilized heart failure outpatients. <i>European Heart Journal</i> , 2008, 29, 1011-1018.	1.0	71
75	Advanced interatrial block predicts new-onset atrial fibrillation and ischemic stroke in patients with heart failure: The 'Bayes' Syndrome-HF study. <i>International Journal of Cardiology</i> , 2018, 271, 174-180.	0.8	71
76	Human Umbilical Cord Blood-Derived Mesenchymal Stem Cells Promote Vascular Growth In Vivo. <i>PLoS ONE</i> , 2012, 7, e49447.	1.1	70
77	Circulating heart failure biomarkers beyond natriuretic peptides: review from the Biomarker Study Group of the Heart Failure Association (<sc>HFA</sc>), European Society of Cardiology (<sc>ESC</sc>). <i>European Journal of Heart Failure</i> , 2021, 23, 1610-1632.	2.9	69
78	Randomized comparison between the invasive and conservative strategies in comorbid elderly patients with non-ST elevation myocardial infarction. <i>European Journal of Internal Medicine</i> , 2016, 35, 89-94.	1.0	68
79	Unraveling the Molecular Mechanism of Action of Empagliflozin in Heart Failure With Reduced Ejection Fraction With or Without Diabetes. <i>JACC Basic To Translational Science</i> , 2019, 4, 831-840.	1.9	65
80	Adecuación en España a las recomendaciones terapéuticas de la Guía de la ESC sobre insuficiencia cardiaca: ESC Heart Failure Long-term Registry. <i>Revista Espanola De Cardiologia</i> , 2015, 68, 785-793.	0.6	64
81	Prognostic value of circulating microRNAs on heart failure-related morbidity and mortality in two large diverse cohorts of general heart failure patients. <i>European Journal of Heart Failure</i> , 2018, 20, 67-75.	2.9	63
82	Adenosine A2A receptors are expressed in human atrial myocytes and modulate spontaneous sarcoplasmic reticulum calcium release. <i>Cardiovascular Research</i> , 2006, 72, 292-302.	1.8	62
83	Depression, antidepressants, and long-term mortality in heart failure. <i>International Journal of Cardiology</i> , 2013, 167, 1217-1225.	0.8	62
84	Antigen carbohydrate 125 as a biomarker in heart failure: a narrative review. <i>European Journal of Heart Failure</i> , 2021, 23, 1445-1457.	2.9	60
85	Using ST2 in cardiovascular patients: a review. <i>Future Cardiology</i> , 2014, 10, 525-539.	0.5	59
86	Weight Loss in Obese Patients With Heart Failure. <i>Journal of the American Heart Association</i> , 2016, 5, e002468.	1.6	59
87	Practical data handling pipeline improves performance of qPCR-based circulating miRNA measurements. <i>Rna</i> , 2017, 23, 811-821.	1.6	58
88	CA125-Guided Diuretic Treatment Versus Usual Care in Patients With Acute Heart Failure and Renal Dysfunction. <i>American Journal of Medicine</i> , 2020, 133, 370-380.e4.	0.6	58
89	Noninvasive Imaging Estimation of Myocardial Iron Repletion Following Administration of Intravenous Iron: The Myocardial IRON Trial. <i>Journal of the American Heart Association</i> , 2020, 9, e014254.	1.6	58
90	Combined Use of the Novel Biomarkers High-Sensitivity Troponin T and ST2 for Heart Failure Risk Stratification vs Conventional Assessment. <i>Mayo Clinic Proceedings</i> , 2013, 88, 234-243.	1.4	57

#	ARTICLE	IF	CITATIONS
91	Clinical Role of CA125 in Worsening Heart Failure. <i>JACC: Heart Failure</i> , 2020, 8, 386-397.	1.9	57
92	Usefulness of Body Mass Index to Characterize Nutritional Status in Patients With Heart Failure. <i>American Journal of Cardiology</i> , 2011, 108, 1166-1170.	0.7	56
93	Statins in Heart Failure: The Paradox Between Large Randomized Clinical Trials and Real Life. <i>Mayo Clinic Proceedings</i> , 2012, 87, 555-560.	1.4	55
94	In vivo experience with natural scaffolds for myocardial infarction: the times they are a-changinâ€™. <i>Stem Cell Research and Therapy</i> , 2015, 6, 248.	2.4	55
95	Combined use of high-sensitivity cardiac troponin T and N-terminal pro-B type natriuretic peptide improves measurements of performance over established mortality risk factors in chronic heart failure. <i>American Heart Journal</i> , 2012, 163, 821-828.	1.2	54
96	Risk Stratification of Mortality in Patients With Heart Failure and Left Ventricular Ejection Fraction >35%. <i>American Journal of Cardiology</i> , 2009, 103, 1003-1010.	0.7	53
97	Hyponatremia, Natriuretic Peptides, and Outcomes in Acutely Decompensated Heart Failure. <i>Circulation: Heart Failure</i> , 2010, 3, 354-361.	1.6	53
98	Acute coronary syndrome and cocaine use: 8-year prevalence and in-hospital outcomes. <i>European Heart Journal</i> , 2011, 32, 1244-1250.	1.0	53
99	Differing prognostic value of pulse pressure in patients with heart failure with reduced or preserved ejection fraction: results from the MAGGIC individual patient meta-analysis. <i>European Heart Journal</i> , 2015, 36, 1106-1114.	1.0	53
100	ST2 and Patient Prognosis in Chronic Heart Failure. <i>American Journal of Cardiology</i> , 2015, 115, 64B-69B.	0.7	53
101	Heart Failure With Preserved Ejection Fraction Infrequently Evolves Toward a Reduced Phenotype in Long-Term Survivors. <i>Circulation: Heart Failure</i> , 2019, 12, e005652.	1.6	53
102	The ESC-EORP EURO-ENDO (European Infective Endocarditis) registry. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2019, 5, 202-207.	1.8	53
103	The obesity paradox in heart failure: Is etiology a key factor?. <i>International Journal of Cardiology</i> , 2013, 166, 601-605.	0.8	52
104	Renal function largely influences Galectin-3 prognostic value in heart failure. <i>International Journal of Cardiology</i> , 2014, 177, 171-177.	0.8	52
105	The Interleukin-1 Axis and Risk of Death in Patients With Acutely Decompensated Heart Failure. <i>Journal of the American College of Cardiology</i> , 2019, 73, 1016-1025.	1.2	52
106	Host cell-derived cardiomyocytes in sex-mismatch cardiac allografts. <i>Cardiovascular Research</i> , 2002, 56, 404-410.	1.8	51
107	Idiopathic dilated cardiomyopathy exhibits defective vascularization and vessel formation. <i>European Journal of Heart Failure</i> , 2007, 9, 995-1002.	2.9	51
108	Predictive Value of Beat-to-Beat QT Variability Index Across the Continuum of Left Ventricular Dysfunction. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2012, 5, 719-727.	2.1	51

#	ARTICLE	IF	CITATIONS
109	Impact of diabetes on the predictive value of heart failure biomarkers. <i>Cardiovascular Diabetology</i> , 2016, 15, 151.	2.7	51
110	Understanding Amino-Terminal Pro-B-Type Natriuretic Peptide in Obesity. <i>American Journal of Cardiology</i> , 2008, 101, S89-S94.	0.7	50
111	No benefit from the obesity paradox for diabetic patients with heart failure. <i>European Journal of Heart Failure</i> , 2016, 18, 851-858.	2.9	49
112	Long-term serial kinetics of N-terminal pro B-type natriuretic peptide and carbohydrate antigen 125 for mortality risk prediction following acute heart failure. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2017, 6, 685-696.	0.4	49
113	Mesenchymal stem cells for cardiac repair: are the actors ready for the clinical scenario?. <i>Stem Cell Research and Therapy</i> , 2017, 8, 238.	2.4	49
114	A bird's-eye view of cell therapy and tissue engineering for cardiac regeneration. <i>Annals of the New York Academy of Sciences</i> , 2012, 1254, 57-65.	1.8	48
115	New electrocardiographic score for the prediction of atrial fibrillation: The MVP ECG risk score (morphology-voltage-P-wave duration). <i>Annals of Noninvasive Electrocardiology</i> , 2019, 24, e12669.	0.5	48
116	Omics phenotyping in heart failure: the next frontier. <i>European Heart Journal</i> , 2020, 41, 3477-3484.	1.0	48
117	Advanced interatrial block and P-wave duration are associated with atrial fibrillation and stroke in older adults with heart disease: the BAYES registry. <i>Europace</i> , 2020, 22, 1001-1008.	0.7	48
118	FGF-4 increases <i>in vitro</i> expansion rate of human adult bone marrow-derived mesenchymal stem cells. <i>Growth Factors</i> , 2007, 25, 71-76.	0.5	47
119	Allogeneic adipose stem cell therapy in acute myocardial infarction. <i>European Journal of Clinical Investigation</i> , 2014, 44, 83-92.	1.7	47
120	The Dynamics of Cardiovascular Biomarkers in non-Elite Marathon Runners. <i>Journal of Cardiovascular Translational Research</i> , 2017, 10, 206-208.	1.1	47
121	Trends in modes of death in heart failure over the last two decades: less sudden death but cancer deaths on the rise. <i>European Journal of Heart Failure</i> , 2019, 21, 1259-1266.	2.9	46
122	Ingeniería tisular cardiaca y corazón bioartificial. <i>Revista Española De Cardiología</i> , 2013, 66, 391-399.	0.6	45
123	Fragility is a key determinant of survival in heart failure patients. <i>International Journal of Cardiology</i> , 2014, 175, 62-66.	0.8	45
124	Head-to-head comparison of two engineered cardiac grafts for myocardial repair: From scaffold characterization to pre-clinical testing. <i>Scientific Reports</i> , 2018, 8, 6708.	1.6	45
125	Prognostic Value and Kinetics of Soluble Natriuretic Peptide in Acute Heart Failure. <i>JACC: Heart Failure</i> , 2015, 3, 641-644.	1.9	44
126	Sacubitril/valsartan and short-term changes in the 6-minute walk test: A pilot study. <i>International Journal of Cardiology</i> , 2018, 252, 136-139.	0.8	44

#	ARTICLE	IF	CITATIONS
127	Atypical advanced interatrial blocks: Definition and electrocardiographic recognition. Journal of Electrocardiology, 2018, 51, 1091-1093.	0.4	44
128	Magnetic Resonance Imaging-Guided Fibrosis Ablation for the Treatment of Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2020, 13, e008707.	2.1	44
129	Intracoronary Administration of Allogeneic Adipose Tissue-Derived Mesenchymal Stem Cells Improves Myocardial Perfusion But Not Left Ventricle Function, in a Translational Model of Acute Myocardial Infarction. Journal of the American Heart Association, 2017, 6, .	1.6	43
130	Soluble ST2 for Prognosis and Monitoring in Heart Failure. Journal of the American College of Cardiology, 2017, 70, 2389-2392.	1.2	43
131	The PCSK9-LDL Receptor Axis and Outcomes in Heart Failure. Journal of the American College of Cardiology, 2017, 70, 2128-2136.	1.2	43
132	Left atrial enlargement and NT-proBNP as predictors of sudden cardiac death in patients with heart failure. European Journal of Heart Failure, 2007, 9, 802-807.	2.9	42
133	Quality of life monitoring in ambulatory heart failure patients: temporal changes and prognostic value. European Journal of Heart Failure, 2013, 15, 103-109.	2.9	42
134	Body mass index, body fat, and nutritional status of patients with heart failure: The PLICA study. Clinical Nutrition, 2015, 34, 1233-1238.	2.3	42
135	Exposure to cardiomyogenic stimuli fails to transdifferentiate human umbilical cord blood-derived mesenchymal stem cells. Basic Research in Cardiology, 2010, 105, 419-430.	2.5	41
136	Soluble ST2 Is a Marker for Acute Cardiac Allograft Rejection. Annals of Thoracic Surgery, 2011, 92, 2118-2124.	0.7	41
137	Neoinnervation and neovascularization of acellular pericardial-derived scaffolds in myocardial infarcts. Stem Cell Research and Therapy, 2015, 6, 108.	2.4	41
138	Early ST elevation myocardial infarction in non-capable percutaneous coronary intervention centres: in situ fibrinolysis vs. percutaneous coronary intervention transfer. European Heart Journal, 2016, 37, 1034-1040.	1.0	41
139	Clinical characteristics, one-year change in ejection fraction and long-term outcomes in patients with heart failure with mid-range ejection fraction: a multicentre prospective observational study in Catalonia (Spain). BMJ Open, 2017, 7, e018719.	0.8	40
140	Relative Efficacy of Sacubitril-Valsartan, Vericiguat, and SGLT2 Inhibitors in Heart Failure with Reduced Ejection Fraction: a Systematic Review and Network Meta-Analysis. Cardiovascular Drugs and Therapy, 2021, 35, 1067-1076.	1.3	40
141	Clinical Risk Prediction in Patients With Left Ventricular Myocardial Noncompaction. Journal of the American College of Cardiology, 2021, 78, 643-662.	1.2	40
142	Local administration of porcine immunomodulatory, chemotactic and angiogenic extracellular vesicles using engineered cardiac scaffolds for myocardial infarction. Bioactive Materials, 2021, 6, 3314-3327.	8.6	40
143	Prognostic Value of QT/RR Slope in Predicting Mortality in Patients with Congestive Heart Failure. Journal of Cardiovascular Electrophysiology, 2008, 19, 1066-1072.	0.8	39
144	Cardiac Tissue Engineering and the Bioartificial Heart. Revista Espanola De Cardiologia (English Ed), 2013, 66, 391-399.	0.4	39

#	ARTICLE	IF	CITATIONS
145	Postinfarction Functional Recovery Driven by a Three-Dimensional Engineered Fibrin Patch Composed of Human Umbilical Cord Blood-Derived Mesenchymal Stem Cells. <i>Stem Cells Translational Medicine</i> , 2015, 4, 956-966.	1.6	39
146	Is Sacubitril/Valsartan (Also) an Antiarrhythmic Drug?. <i>Circulation</i> , 2018, 138, 551-553.	1.6	39
147	Average T-wave alternans activity in ambulatory ECG records predicts sudden cardiac death in patients with chronic heart failure. <i>Heart Rhythm</i> , 2012, 9, 383-389.	0.3	38
148	Left Atrial Geometry Improves Risk Prediction of Thromboembolic Events in Patients With Atrial Fibrillation. <i>Journal of Cardiovascular Electrophysiology</i> , 2016, 27, 804-810.	0.8	38
149	Usefulness of Right Ventricular to Pulmonary Circulation Coupling as an Indicator of Risk for Recurrent Admissions in Heart Failure With Preserved Ejection Fraction. <i>American Journal of Cardiology</i> , 2019, 124, 567-572.	0.7	38
150	In vitro comparative study of two decellularization protocols in search of an optimal myocardial scaffold for recellularization. <i>American Journal of Translational Research (discontinued)</i> , 2015, 7, 558-73.	0.0	37
151	Transient biventricular dysfunction following pericardiocentesis. <i>European Journal of Heart Failure</i> , 2006, 8, 102-104.	2.9	36
152	Serial NT-proBNP monitoring and outcomes in outpatients with decompensation of heart failure. <i>International Journal of Cardiology</i> , 2007, 120, 338-343.	0.8	36
153	Fibrin, the preferred scaffold for cell transplantation after myocardial infarction? An old molecule with a new life. <i>Journal of Tissue Engineering and Regenerative Medicine</i> , 2017, 11, 2304-2313.	1.3	36
154	Mesenchymal Stem Cells Induce Expression of CD73 in Human Monocytes In Vitro and in a Swine Model of Myocardial Infarction In Vivo. <i>Frontiers in Immunology</i> , 2017, 8, 1577.	2.2	36
155	Association between loop diuretic dose changes and outcomes in chronic heart failure: observations from the ESCâ€œORP Heart Failure Longâ€œTerm Registry. <i>European Journal of Heart Failure</i> , 2020, 22, 1424-1437.	2.9	36
156	Hemoglobin and N-terminal pro-brain natriuretic peptide: Independent and synergistic predictors of mortality in patients with acute heart failure. <i>Clinica Chimica Acta</i> , 2007, 381, 145-150.	0.5	35
157	Differential Diagnosis of rSâ€œ Pattern in Leads V₁-V₂. <i>Comprehensive Review and Proposed Algorithm.</i> , 2015, 20, 7-17.		35
158	Sacubitril/valsartan eligibility and outcomes in the ESCâ€œORPâ€œHFA Heart Failure Longâ€œTerm Registry: bridging between European Medicines Agency/Food and Drug Administration label, the PARADIGMâ€œHF trial, ESC guidelines, and real world. <i>European Journal of Heart Failure</i> , 2019, 21, 1383-1397.	2.9	35
159	Impact of Kidney Dysfunction on Plasma and Urinary Nâ€œterminal Proâ€œBâ€œType Natriuretic Peptide in Patients With Acute Heart Failure. <i>Congestive Heart Failure</i> , 2010, 16, 214-220.	2.0	34
160	Transposition of a pericardial-derived vascular adipose flap for myocardial salvage after infarct. <i>Cardiovascular Research</i> , 2011, 91, 659-667.	1.8	34
161	Transradial percutaneous coronary intervention in cardiogenic shock: A single-center experience. <i>American Heart Journal</i> , 2013, 165, 280-285.	1.2	34
162	Head-to-head comparison of high-sensitivity troponin T and sensitive-contemporary troponin I regarding heart failure risk stratification. <i>Clinica Chimica Acta</i> , 2013, 426, 18-24.	0.5	34

#	ARTICLE	IF	CITATIONS
163	Hypoxia Induces Metalloproteinase-9 Activation and Human Vascular Smooth Muscle Cell Migration Through Low-Density Lipoprotein Receptor-Related Protein 1-Mediated Pyk2 Phosphorylation. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2013, 33, 2877-2887.	1.1	34
164	Online monitoring of myocardial bioprosthesis for cardiac repair. <i>International Journal of Cardiology</i> , 2014, 174, 654-661.	0.8	34
165	Antígeno carbohidrato 125 en insuficiencia cardíaca. Nueva era en la monitorización y control del tratamiento. <i>Medicina Clínica</i> , 2019, 152, 266-273.	0.3	34
166	Detecting Vulnerable Plaque Using Peripheral Blood: Inflammatory and Cellular Markers. <i>Journal of Interventional Cardiology</i> , 2003, 16, 231-242.	0.5	33
167	Bioluminescence imaging of cardiomyogenic and vascular differentiation of cardiac and subcutaneous adipose tissue-derived progenitor cells in fibrin patches in a myocardium infarct model. <i>International Journal of Cardiology</i> , 2013, 169, 288-295.	0.8	33
168	Predictive biomarkers for death and rehospitalization in comorbid frail elderly heart failure patients. <i>BMC Geriatrics</i> , 2018, 18, 109.	1.1	33
169	Silk-Reinforced Collagen Hydrogels with Raised Multiscale Stiffness for Mesenchymal Cells 3D Culture. <i>Tissue Engineering - Part A</i> , 2020, 26, 358-370.	1.6	33
170	Meteorin-like/Meteorin- β^2 protects heart against cardiac dysfunction. <i>Journal of Experimental Medicine</i> , 2021, 218, .	4.2	33
171	A New Electrocardiographic Algorithm to Locate the Occlusion in Left Anterior Descending Coronary Artery. <i>Clinical Cardiology</i> , 2009, 32, E1-6.	0.7	32
172	Identification of Temporal and Region-Specific Myocardial Gene Expression Patterns in Response to Infarction in Swine. <i>PLoS ONE</i> , 2013, 8, e54785.	1.1	32
173	Bio-profiling and bio-prognostication of chronic heart failure with mid-range ejection fraction. <i>International Journal of Cardiology</i> , 2018, 257, 188-192.	0.8	32
174	High-sensitivity troponin T, NT-proBNP and glomerular filtration rate: A multimarker strategy for risk stratification in chronic heart failure. <i>International Journal of Cardiology</i> , 2019, 277, 166-172.	0.8	32
175	Factors associated with plasma antigen carbohydrate 125 and amino-terminal pro-B-type natriuretic peptide concentrations in acute heart failure. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2020, 9, 437-447.	0.4	32
176	<scp>COVID</scp>-19 vaccination in patients with heart failure: a position paper of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2021, 23, 1806-1818.	2.9	32
177	Bone marrow endothelial dysfunction promotes myeloid cell expansion in cardiovascular disease. , 2022, 1, 28-44.		32
178	Soluble ST2 Monitoring Provides Additional Risk Stratification for Outpatients With Decompensated Heart Failure. <i>Revista Española De Cardiología (English Ed)</i> , 2010, 63, 1171-1178.	0.4	31
179	Bioluminescence imaging: a shining future for cardiac regeneration. <i>Journal of Cellular and Molecular Medicine</i> , 2013, 17, 693-703.	1.6	31
180	ST2 Pathogenetic Profile in Ambulatory Heart Failure Patients. <i>Journal of Cardiac Failure</i> , 2015, 21, 355-361.	0.7	31

#	ARTICLE	IF	CITATIONS
181	Nepriylsin and Natriuretic Peptide Regulation in Heart Failure. <i>Current Heart Failure Reports</i> , 2016, 13, 151-157.	1.3	31
182	Prognostic Value of Serial Measurements of Soluble Suppression of Tumorigenicity 2 and Galectin-3 in Ambulatory Patients With Chronic Heart Failure. <i>Journal of Cardiac Failure</i> , 2016, 22, 249-255.	0.7	31
183	Gender-Related Differences in Heart Failure Biomarkers. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 617705.	1.1	31
184	Obesity paradox and risk of sudden death in heart failure. <i>American Heart Journal</i> , 2011, 161, 158-164.	1.2	30
185	Anti-Ro Antibodies and Reversible Atrioventricular Block. <i>New England Journal of Medicine</i> , 2013, 368, 2335-2337.	13.9	30
186	Challenging the two concepts in determining the appropriate pre-discharge N-terminal pro-brain natriuretic peptide treatment target in acute decompensated heart failure patients: absolute or relative discharge levels?. <i>European Journal of Heart Failure</i> , 2015, 17, 936-944.	2.9	30
187	Structural Heart Disease and ST2: Cross-Sectional and Longitudinal Associations With Echocardiography. <i>American Journal of Cardiology</i> , 2015, 115, 59B-63B.	0.7	30
188	ST2 in Heart Failure. <i>Circulation: Heart Failure</i> , 2018, 11, e005582.	1.6	30
189	Protein-based cardiogenic shock patient classifier. <i>European Heart Journal</i> , 2019, 40, 2684-2694.	1.0	30
190	Mini nutritional assessment is a better predictor of mortality than subjective global assessment in heart failure out-patients. <i>Clinical Nutrition</i> , 2019, 38, 2740-2746.	2.3	30
191	Sacubitril-Valsartan, Clinical Benefits and Related Mechanisms of Action in Heart Failure With Reduced Ejection Fraction. A Review. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 754499.	1.1	30
192	New electrocardiographic diagnostic criteria for the pathologic R waves in leads V1 and V2 of anatomically lateral myocardial infarction. <i>Journal of Electrocardiology</i> , 2008, 41, 413-418.	0.4	29
193	Incidence and predictors of new-onset atrioventricular block requiring pacemaker implantation after sutureless aortic valve replacement. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2016, 23, 861-868.	0.5	29
194	New Electrocardiographic Algorithm for the Diagnosis of Acute Myocardial Infarction in Patients With Left Bundle Branch Block. <i>Journal of the American Heart Association</i> , 2020, 9, e015573.	1.6	29
195	Cardiac remodelling Part 1: From cells and tissues to circulating biomarkers. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2022, 24, 927-943.	2.9	29
196	Colchicine for large pericardial effusion. <i>Clinical Cardiology</i> , 1998, 21, 143-144.	0.7	28
197	Evaluation of a telemedicine system for heart failure patients: feasibility, acceptance rate, satisfaction and changes in patient behavior: results from the CARME (Catalan Remote Management Evaluation) study. <i>European Journal of Cardiovascular Nursing</i> , 2012, 11, 410-418.	0.4	28
198	Long-term Prognostic Value for Patients with Chronic Heart Failure of Estimated Glomerular Filtration Rate Calculated with the New CKD-EPI Equations Containing Cystatin C. <i>Clinical Chemistry</i> , 2014, 60, 481-489.	1.5	28

#	ARTICLE	IF	CITATIONS
199	Educational level and self-care behaviour in patients with heart failure before and after nurse educational intervention. <i>European Journal of Cardiovascular Nursing</i> , 2014, 13, 459-465.	0.4	28
200	A novel wearable vest for tracking pulmonary congestion in acutely decompensated heart failure. <i>International Journal of Cardiology</i> , 2014, 177, 199-201.	0.8	28
201	Reduced Irregularity of Ventricular Response During Atrial Fibrillation and Long-term Outcome in Patients With Heart Failure. <i>American Journal of Cardiology</i> , 2015, 116, 1071-1075.	0.7	28
202	¿Debemos anticoagular a pacientes en alto riesgo de sufrir fibrilación auricular?. <i>Revista Española De Cardiología</i> , 2016, 69, 374-376.	0.6	28
203	Colchicine in Pericarditis. <i>European Heart Journal</i> , 2017, 38, 1706-1709.	1.0	28
204	Noninvasive Assessment of an Engineered Bioactive Graft in Myocardial Infarction: Impact on Cardiac Function and Scar Healing. <i>Stem Cells Translational Medicine</i> , 2017, 6, 647-655.	1.6	28
205	Surface ECG interatrial block-guided treatment for stroke prevention: rationale for an attractive hypothesis. <i>BMC Cardiovascular Disorders</i> , 2017, 17, 211.	0.7	28
206	Interatrial block, frailty and prognosis in elderly patients with myocardial infarction. <i>Journal of Electrocardiology</i> , 2018, 51, 1-7.	0.4	28
207	Revisiting the obesity paradox in heart failure: Per cent body fat as predictor of biomarkers and outcome. <i>European Journal of Preventive Cardiology</i> , 2019, 26, 1751-1759.	0.8	28
208	Perspectives on Directions and Priorities for Future Preclinical Studies in Regenerative Medicine. <i>Circulation Research</i> , 2019, 124, 938-951.	2.0	28
209	CA125 outperforms NT-proBNP in acute heart failure with severe tricuspid regurgitation. <i>International Journal of Cardiology</i> , 2020, 308, 54-59.	0.8	28
210	Optimising clinical trials in acute myocardial infarction complicated by cardiogenic shock: a statement from the 2020 Critical Care Clinical Trialists Workshop. <i>Lancet Respiratory Medicine</i> , 2021, 9, 1192-1202.	5.2	28
211	Early effects of empagliflozin on exercise tolerance in patients with heart failure: A pilot study. <i>Clinical Cardiology</i> , 2018, 41, 476-480.	0.7	27
212	First-in-human PeriCord cardiac bioimplant: Scalability and GMP manufacturing of an allogeneic engineered tissue graft. <i>EBioMedicine</i> , 2020, 54, 102729.	2.7	27
213	Cardiovascular disease and COVID-19: les liaisons dangereuses. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 1017-1025.	0.8	27
214	Practical outpatient management of worsening chronic heart failure. <i>European Journal of Heart Failure</i> , 2022, 24, 750-761.	2.9	27
215	Chimerism and microchimerism of the human heart: evidence for cardiac regeneration. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2007, 4, S40-S45.	3.3	26
216	Bioelectrical impedance vector analysis and clinical outcomes in patients with acute heart failure. <i>Journal of Cardiovascular Medicine</i> , 2016, 17, 283-290.	0.6	26

#	ARTICLE	IF	CITATIONS
217	Prediction of survival and magnitude of reverse remodeling using the ST2-R2 score in heart failure: A multicenter study. <i>International Journal of Cardiology</i> , 2016, 204, 242-247.	0.8	26
218	Electromechanical Conditioning of Adult Progenitor Cells Improves Recovery of Cardiac Function After Myocardial Infarction. <i>Stem Cells Translational Medicine</i> , 2017, 6, 970-981.	1.6	26
219	Proteomic signature of circulating extracellular vesicles in dilated cardiomyopathy. <i>Laboratory Investigation</i> , 2018, 98, 1291-1299.	1.7	26
220	Transitioning from usual care to biomarker-based personalized and precision medicine in heart failure: call for action. <i>European Heart Journal</i> , 2018, 39, 2793-2799.	1.0	26
221	Cancer antigen-125 and outcomes in acute heart failure: a systematic review and meta-analysis. <i>Heart Asia</i> , 2018, 10, e011044.	1.1	26
222	Circulating levels and prognostic value of soluble ST2 in heart failure are less influenced by age than N-terminal pro-B-type natriuretic peptide and high-sensitivity troponin T. <i>European Journal of Heart Failure</i> , 2020, 22, 2078-2088.	2.9	26
223	Association between right-sided cardiac function and ultrasound-based pulmonary congestion on acutely decompensated heart failure: findings from a pooled analysis of four cohort studies. <i>Clinical Research in Cardiology</i> , 2021, 110, 1181-1192.	1.5	26
224	Head-to-head comparison of contemporary heart failure risk scores. <i>European Journal of Heart Failure</i> , 2021, 23, 2035-2044.	2.9	26
225	Hypoxia exacerbates Ca ²⁺ -handling disturbances induced by very low density lipoproteins (VLDL) in neonatal rat cardiomyocytes. <i>Journal of Molecular and Cellular Cardiology</i> , 2011, 50, 894-902.	0.9	25
226	Cardiac adipose tissue: A new frontier for cardiac regeneration?. <i>International Journal of Cardiology</i> , 2013, 167, 22-25.	0.8	25
227	Multiple biomarker strategies for risk stratification in heart failure. <i>Clinica Chimica Acta</i> , 2015, 443, 120-125.	0.5	25
228	Characterization and implications of the dynamics of eosinophils in blood and in the infarcted myocardium after coronary reperfusion. <i>PLoS ONE</i> , 2018, 13, e0206344.	1.1	25
229	Soluble ST2 promotes oxidative stress and inflammation in cardiac fibroblasts: an <i>in vitro</i> and <i>in vivo</i> study in aortic stenosis. <i>Clinical Science</i> , 2019, 133, 1537-1548.	1.8	25
230	Effect of COMBinAtion therapy with remote ischemic conditioning and exenatide on the Myocardial Infarct size: a two-by-two factorial randomized trial (COMBAT-MI). <i>Basic Research in Cardiology</i> , 2021, 116, 4.	2.5	25
231	Resumen de los ensayos clínicos presentados en las Sesiones Científicas Anuales de la American Heart Association (Orlando, Estados Unidos, 14-18 de noviembre de 2009). <i>Revista Espanola De Cardiologia</i> , 2010, 63, 190-199.	0.6	24
232	Should We Anticoagulate Patients at High Risk of Atrial Fibrillation?. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2016, 69, 374-376.	0.4	24
233	Effect of low-dose colchicine in acute and chronic coronary syndromes: A systematic review and meta-analysis. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13464.	1.7	24
234	Engineered 3D bioimplants using elastomeric scaffold, self-assembling peptide hydrogel, and adipose tissue-derived progenitor cells for cardiac regeneration. <i>American Journal of Translational Research (discontinued)</i> , 2014, 6, 291-301.	0.0	24

#	ARTICLE	IF	CITATIONS
235	Post-infarction scar coverage using a pericardial-derived vascular adipose flap. Pre-clinical results. <i>International Journal of Cardiology</i> , 2013, 166, 469-474.	0.8	23
236	Physiological conditioning by electric field stimulation promotes cardiomyogenic gene expression in human cardiomyocyte progenitor cells. <i>Stem Cell Research and Therapy</i> , 2014, 5, 93.	2.4	23
237	Neprilysin in Heart Failure. <i>JACC: Heart Failure</i> , 2015, 3, 637-640.	1.9	23
238	Multimarker Strategy for Heart Failure Prognostication. Value of Neurohormonal Biomarkers: Neprilysin vs NT-proBNP. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2015, 68, 1075-1084.	0.4	23
239	Soluble neprilysin retains catalytic activity in heart failure. <i>Journal of Heart and Lung Transplantation</i> , 2016, 35, 684-685.	0.3	23
240	Entrenamiento de la musculatura inspiratoria y la electroestimulación muscular funcional en el tratamiento de la insuficiencia cardiaca con función sistólica conservada: estudio TRAINING-HF. <i>Revista Espanola De Cardiologia</i> , 2019, 72, 288-297.	0.6	23
241	Decoding empagliflozin's molecular mechanism of action in heart failure with preserved ejection fraction using artificial intelligence. <i>Scientific Reports</i> , 2021, 11, 12025.	1.6	23
242	Integration of imaging and circulating biomarkers in heart failure: a consensus document by the Biomarkers and Imaging Study Groups of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2021, 23, 1577-1596.	2.9	23
243	Cardiac chimerism in recipients of peripheral-blood and bone marrow stem cells. <i>European Journal of Heart Failure</i> , 2004, 6, 399-402.	2.9	22
244	Bioelectrical impedance vector analysis (BIVA) in stable and non-stable heart failure patients: A pilot study. <i>International Journal of Cardiology</i> , 2011, 146, 262-264.	0.8	22
245	Umbilical cord blood for cardiovascular cell therapy: from promise to fact. <i>Annals of the New York Academy of Sciences</i> , 2012, 1254, 66-70.	1.8	22
246	Effect of Fragility on Quality of Life in Patients With Heart Failure. <i>American Journal of Cardiology</i> , 2013, 112, 1785-1789.	0.7	22
247	Comparison of two preclinical myocardial infarct models: coronary coil deployment versus surgical ligation. <i>Journal of Translational Medicine</i> , 2014, 12, 137.	1.8	22
248	Resumen de los ensayos clínicos presentados en las Sesiones Científicas Anuales del American College of Cardiology (Washington D.C., Estados Unidos, 29-31 de marzo de 2014). <i>Revista Espanola De Cardiologia</i> , 2014, 67, 479.e1-479.e7.	0.6	22
249	Arrhythmogenic right ventricular dysplasia/cardiomyopathy: an electrocardiogram-based review. <i>Europace</i> , 2018, 20, f3-f12.	0.7	22
250	Intrarenal venous flow in cardiorenal syndrome: a shining light into the darkness. <i>ESC Heart Failure</i> , 2018, 5, 1173-1175.	1.4	22
251	Relation of Advanced Interatrial Block to Risk of Atrial Fibrillation and Stroke. <i>American Journal of Cardiology</i> , 2020, 125, 1745-1748.	0.7	22
252	Therapeutic inertia in the pharmacological management of heart failure with reduced ejection fraction. <i>ESC Heart Failure</i> , 2022, 9, 2063-2069.	1.4	22

#	ARTICLE	IF	CITATIONS
253	Cardiac remodelling Part 2: Clinical, imaging and laboratory findings. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2022, 24, 944-958.	2.9	22
254	Short-term effects of dapagliflozin on maximal functional capacity in heart failure with reduced ejection fraction (DAPA-HF): a randomized clinical trial. <i>European Journal of Heart Failure</i> , 2022, 24, 1816-1826.	2.9	22
255	Resumen de estudios clínicos presentados en el Congreso de 2010 de la European Society of Cardiology (28 de agosto-1 de septiembre de 2010, Estocolmo, Suecia). <i>Revista Espanola De Cardiologia</i> , 2010, 63, 1292-1303.	0.6	21
256	Noninvasive Remote Telemonitoring for Ambulatory Patients With Heart Failure: Effect on Number of Hospitalizations, Days in Hospital, and Quality of Life. <i>CARME (Catalan Remote Management) Trial</i> . <i>Circulation</i> , 2011, 124, 1011-1019.	0.0	617
257	Inverse relationship between raft LRP1 localization and non-raft ERK1,2/MMP9 activation in idiopathic dilated cardiomyopathy: Potential impact in ventricular remodeling. <i>International Journal of Cardiology</i> , 2014, 176, 805-814.	0.8	21
258	Preclinical Evaluation of the Immunomodulatory Properties of Cardiac Adipose Tissue Progenitor Cells Using Umbilical Cord Blood Mesenchymal Stem Cells: A Direct Comparative Study. <i>BioMed Research International</i> , 2015, 2015, 1-9.	0.9	21
259	ST2 and Multimarker Testing in Acute Decompensated Heart Failure. <i>American Journal of Cardiology</i> , 2015, 115, 38B-43B.	0.7	21
260	Adherence to the ESC Heart Failure Treatment Guidelines in Spain: ESC Heart Failure Long-term Registry. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2015, 68, 785-793.	0.4	21
261	Early serum creatinine changes and outcomes in patients admitted for acute heart failure: the cardio-renal syndrome revisited. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2017, 6, 430-440.	0.4	21
262	Early Postdischarge STOP-HF-Clinic Reduces 30-day Readmissions in Old and Frail Patients With Heart Failure. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2017, 70, 631-638.	0.4	21
263	Circulating miR-1254 predicts ventricular remodeling in patients with ST-Segment-Elevation Myocardial Infarction: A cardiovascular magnetic resonance study. <i>Scientific Reports</i> , 2018, 8, 15115.	1.6	21
264	ST2 and left ventricular remodeling after ST-segment elevation myocardial infarction: A cardiac magnetic resonance study. <i>International Journal of Cardiology</i> , 2018, 270, 336-342.	0.8	21
265	Short-term changes in left and right systolic function following ferric carboxymaltose: a substudy of the MyocardialIRON trial. <i>ESC Heart Failure</i> , 2020, 7, 4222-4230.	1.4	21
266	Interatrial block and cognitive impairment in the BAYES prospective registry. <i>International Journal of Cardiology</i> , 2020, 321, 95-98.	0.8	21
267	Empagliflozin improves post-infarction cardiac remodeling through GTP enzyme cyclohydrolase 1 and irrespective of diabetes status. <i>Scientific Reports</i> , 2020, 10, 13553.	1.6	21
268	Body mass index and outcomes in ischaemic versus non-ischaemic heart failure across the spectrum of ejection fraction. <i>European Journal of Preventive Cardiology</i> , 2020, , 204748732092761.	0.8	21
269	Mini Nutritional Assessment Short Form is a morbi-mortality predictor in outpatients with heart failure and mid-range left ventricular ejection fraction. <i>Clinical Nutrition</i> , 2020, 39, 3395-3401.	2.3	21
270	Creating the bioartificial myocardium for cardiac repair: challenges and clinical targets. <i>Expert Review of Cardiovascular Therapy</i> , 2013, 11, 1701-1711.	0.6	20

#	ARTICLE	IF	CITATIONS
271	A Cell-Enriched Engineered Myocardial Graft Limits Infarct Size and Improves Cardiac Function. <i>JACC Basic To Translational Science</i> , 2016, 1, 360-372.	1.9	20
272	Serum Neprilysin and Recurrent Admissions in Patients With Heart Failure. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	20
273	Functional Mitral Regurgitation Predicts Short-Term Adverse Events in Patients With Acute Heart Failure and Reduced Left Ventricular Ejection Fraction. <i>American Journal of Cardiology</i> , 2017, 120, 1344-1348.	0.7	20
274	Barcelona Bioâ€œHF Calculator Version 2.0: incorporation of angiotensin II receptor blocker neprilysin inhibitor (ARNI) and risk for heart failure hospitalization. <i>European Journal of Heart Failure</i> , 2018, 20, 938-940.	2.9	20
275	Microvascular Obstruction in ST-Segment Elevation Myocardial Infarction: Looking Back to Move Forward. <i>Focus on CMR. Journal of Clinical Medicine</i> , 2019, 8, 1805.	1.0	20
276	Molecular signature of cardiogenic shock. <i>European Heart Journal</i> , 2020, 41, 3839-3848.	1.0	20
277	Particle size and cholesterol content of circulating HDL correlate with cardiovascular death in chronic heart failure. <i>Scientific Reports</i> , 2021, 11, 3141.	1.6	20
278	Re-appraisal of the obesity paradox in heart failure: a meta-analysis of individual data. <i>Clinical Research in Cardiology</i> , 2021, 110, 1280-1291.	1.5	20
279	NT-proBNP for Risk Prediction in Heartâ€œFailure. <i>JACC: Heart Failure</i> , 2021, 9, 653-663.	1.9	20
280	Distinct left bundle branch block pattern in ischemic and non-ischemic dilated cardiomyopathy. <i>European Journal of Heart Failure</i> , 2003, 5, 165-170.	2.9	19
281	Resumen de los ensayos clÃƒnicos presentados en las Sesiones CientÃƒficas Anuales del American College of Cardiology (Atlanta, Estados Unidos, 14-16 de marzo de 2010). <i>Revista Espanola De Cardiologia</i> , 2010, 63, 695-707.	0.6	19
282	Multimarker Testing With ST2 in Chronic Heart Failure. <i>American Journal of Cardiology</i> , 2015, 115, 76B-80B.	0.7	19
283	Circulating Omega-3 Fatty Acids and Incident Adverse Events in Patients With Acute Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2020, 76, 2089-2097.	1.2	19
284	Transitioning from Preclinical to Clinical Heart Failure with Preserved Ejection Fraction: A Mechanistic Approach. <i>Journal of Clinical Medicine</i> , 2020, 9, 1110.	1.0	19
285	Sacubitril/valsartan for the management of heart failure: A perspective viewpoint on current evidence. <i>International Journal of Cardiology</i> , 2021, 327, 138-145.	0.8	19
286	Are mesenchymal stem cells and derived extracellular vesicles valuable to halt the COVID-19 inflammatory cascade? Current evidence and future perspectives. <i>Thorax</i> , 2021, 76, 196-200.	2.7	19
287	Is acute heart failure a distinctive disorder? An analysis from BIOSTATâ€œCHF. <i>European Journal of Heart Failure</i> , 2021, 23, 43-57.	2.9	19
288	Pressure rinsing of coronary stents immediately before implantation reduces inflammation and neointimal hyperplasia. <i>Journal of the American College of Cardiology</i> , 2001, 38, 562-568.	1.2	18

#	ARTICLE	IF	CITATIONS
289	Hypoxia-driven sarcoplasmic/endoplasmic reticulum calcium ATPase 2 (SERCA2) downregulation depends on low-density lipoprotein receptor-related protein 1 (LRP1)-signalling in cardiomyocytes. <i>Journal of Molecular and Cellular Cardiology</i> , 2015, 85, 25-36.	0.9	18
290	Importance of iron deficiency in patients with chronic heart failure as a predictor of mortality and hospitalizations: insights from an observational cohort study. <i>BMC Cardiovascular Disorders</i> , 2018, 18, 206.	0.7	18
291	Comorbidities, Fragility, and Quality of Life in Heart Failure Patients With Midrange Ejection Fraction. <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2018, 2, 176-185.	1.2	18
292	Microencapsulated Insulin-Like Growth Factor-1 therapy improves cardiac function and reduces fibrosis in a porcine acute myocardial infarction model. <i>Scientific Reports</i> , 2020, 10, 7166.	1.6	18
293	Sex-Related Differences in the Mechanism of Functional Tricuspid Regurgitation. <i>Heart Lung and Circulation</i> , 2021, 30, e16-e22.	0.2	18
294	Persistent Pulmonary Hypertension in Corrected Valvular Heart Disease: Hemodynamic Insights and Long-Term Survival. <i>Journal of the American Heart Association</i> , 2021, 10, e019949.	1.6	18
295	CA125 but not NT-proBNP predicts the presence of a congestive intrarenal venous flow in patients with acute heart failure. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021, 10, 475-483.	0.4	18
296	Awake venoarterial extracorporeal membrane oxygenation for refractory cardiogenic shock. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021, 10, 585-594.	0.4	18
297	Sex differences on new-onset heart failure in patients with known or suspected coronary artery disease. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 1711-1719.	0.8	18
298	Comparación entre CA125 y NT-proBNP para valorar la congestión en insuficiencia cardíaca aguda. <i>Medicina Clínica</i> , 2021, 156, 589-594.	0.3	18
299	Cardiovascular Complications of Interatrial Conduction Block. <i>Journal of the American College of Cardiology</i> , 2022, 79, 1199-1211.	1.2	18
300	Head-to-head comparison between recommendations by the ESC and ACC/AHA/HFSA heart failure guidelines. <i>European Journal of Heart Failure</i> , 2022, 24, 916-926.	2.9	18
301	Development and validation of a decision support tool for the diagnosis of acute heart failure: systematic review, meta-analysis, and modelling study. <i>BMJ</i> , The, 0, , e068424.	3.0	18
302	Electrocardiographic and Clinical Precursors of Ventricular Fibrillation: Chain of Events. <i>Journal of Cardiovascular Electrophysiology</i> , 1995, 6, 410-417.	0.8	17
303	N-terminal pro-brain natriuretic peptide reflects pulmonary capillary leakage in patients with acute dyspnea. <i>American Journal of Cardiology</i> , 2004, 94, 669-670.	0.7	17
304	Low Atrial Fibrillatory Rate Is Associated With Poor Outcome in Patients With Mild to Moderate Heart Failure. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2012, 5, 77-83.	2.1	17
305	Resumen de los ensayos clínicos presentados en las Sesiones Científicas Anuales de la American Heart Association (Los Ángeles, California, Estados Unidos, 3-7 de noviembre de 2012). <i>Revista Española De Cardiología</i> , 2013, 66, 55.e1-55.e11.	0.6	17
306	Thrombus age, clinical presentation, and reperfusion grade in myocardial infarction. <i>Cardiovascular Pathology</i> , 2014, 23, 126-130.	0.7	17

#	ARTICLE	IF	CITATIONS
307	Three-Dimensional Cultures of Human Subcutaneous Adipose Tissue-Derived Progenitor Cells Based on RAD16-I Self-Assembling Peptide. <i>Tissue Engineering - Part C: Methods</i> , 2016, 22, 113-124.	1.1	17
308	Time-to-first-event versus recurrent-event analysis: points to consider for selecting a meaningful analysis strategy in clinical trials with composite endpoints. <i>Clinical Research in Cardiology</i> , 2018, 107, 437-443.	1.5	17
309	Prognostic value of the Stanniocalcin-2/PAPP-A/IGFBP-4 axis in ST-segment elevation myocardial infarction. <i>Cardiovascular Diabetology</i> , 2018, 17, 63.	2.7	17
310	Management of Nonagenarian Patients With Severe Aortic Stenosis: The Role of Comorbidity. <i>Heart Lung and Circulation</i> , 2018, 27, 219-226.	0.2	17
311	Prognostic of Interatrial Block after an Acute ST-Segment Elevation Myocardial Infarction. <i>Cardiology</i> , 2019, 142, 109-115.	0.6	17
312	Pulmonary hypertension and right ventricular dysfunction in heart failure: prognosis and 15-year prospective longitudinal trajectories in survivors. <i>European Journal of Heart Failure</i> , 2020, 22, 1214-1225.	2.9	17
313	The prognostic impact of mechanical atrial dysfunction and atrial fibrillation in heart failure with preserved ejection fraction. <i>European Heart Journal Cardiovascular Imaging</i> , 2021, 23, 74-84.	0.5	17
314	Sacubitril/valsartan affects pulmonary arterial pressure in heart failure with preserved ejection fraction and pulmonary hypertension. <i>ESC Heart Failure</i> , 2022, 9, 2170-2180.	1.4	17
315	Association of Blood Pressure and Its Evolving Changes With the Survival of Patients With Heart Failure. <i>Journal of Cardiac Failure</i> , 2008, 14, 561-568.	0.7	16
316	New York Heart Association class versus amino-terminal pro-B type natriuretic peptide for acute heart failure prognosis. <i>Biomarkers</i> , 2010, 15, 307-314.	0.9	16
317	Umbilical cord blood-derived mesenchymal stem cells: New therapeutic weapons for idiopathic dilated cardiomyopathy?. <i>International Journal of Cardiology</i> , 2014, 177, 809-818.	0.8	16
318	Heart failure with mid-range ejection fraction: a transition phenotype?. <i>European Journal of Heart Failure</i> , 2017, 19, 1635-1637.	2.9	16
319	Prognostic Value of New-Generation Troponins in ST-Segment Elevation Myocardial Infarction in the Modern Era: The RUTIA-STEMI Study. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	16
320	Left ventricular ejection fraction in heart failure: a clinician's perspective about a dynamic and imperfect parameter, though still convenient and a cornerstone for patient classification and management. <i>European Journal of Heart Failure</i> , 2018, 20, 433-435.	2.9	16
321	Testosterone Replacement Therapy in Deficient Patients With Chronic Heart Failure. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2018, 23, 543-550.	1.0	16
322	A bio-clinical approach for prediction of sudden cardiac death in outpatients with heart failure: The ST2-SCD score. <i>International Journal of Cardiology</i> , 2019, 293, 148-152.	0.8	16
323	Functional tricuspid regurgitation and recurrent admissions in patients with acute heart failure. <i>International Journal of Cardiology</i> , 2019, 291, 83-88.	0.8	16
324	Toward Standardization of Mesenchymal Stromal Cell-Derived Extracellular Vesicles for Therapeutic Use: A Call for Action. <i>Proteomics</i> , 2019, 19, e1800397.	1.3	16

#	ARTICLE	IF	CITATIONS
325	Hiperpotasemia en pacientes con insuficiencia cardiaca en España y su impacto en las recomendaciones. Registro ESC-EORP-HFA Heart Failure Long-Term. Revista Espanola De Cardiologia, 2020, 73, 313-323.	0.6	16
326	Altered GDF15 and FGF21 Levels in Response to Strenuous Exercise: A Study in Marathon Runners. Frontiers in Physiology, 2020, 11, 550102.	1.3	16
327	Trends in Short- and Long-Term ST-Segment Elevation Myocardial Infarction Prognosis Over 3 Decades: A Mediterranean Population-Based ST-Segment Elevation Myocardial Infarction Registry. Journal of the American Heart Association, 2020, 9, e017159.	1.6	16
328	Biomarkers in Heart Failure with Preserved Ejection Fraction. Cardiac Failure Review, 0, 8, .	1.2	16
329	Optimizing electrocardiographic interpretation in acute ST-elevation myocardial infarction may be very beneficial. American Heart Journal, 2011, 162, e1-e2.	1.2	15
330	Resumen de los ensayos clínicos presentados en las Sesiones Científicas Anuales de la American Heart Association (Chicago, Estados Unidos, 13-17 de noviembre de 2010). Revista Espanola De Cardiologia, 2011, 64, 59.e1-59.e8.	0.6	15
331	The Challenges for Cardiac Vascular Precursor Cell Therapy: Lessons from a Very Elusive Precursor. Journal of Vascular Research, 2013, 50, 304-323.	0.6	15
332	Results of Primary Percutaneous Coronary Intervention in Patients ≥ 75 Years Treated by the Transradial Approach. American Journal of Cardiology, 2014, 113, 452-456.	0.7	15
333	Anti-Ro/SSA antibodies and cardiac rhythm disturbances: Present and future perspectives. International Journal of Cardiology, 2015, 184, 244-250.	0.8	15
334	Changes in myocardial iron content following administration of intravenous iron (Myocardial IRON): Study design. Clinical Cardiology, 2018, 41, 729-735.	0.7	15
335	Risk Estimation in Type 2 Myocardial Infarction and Myocardial Injury: The TARRACO Risk Score. American Journal of Medicine, 2019, 132, 217-226.	0.6	15
336	Circulating levels of $\langle scp \rangle$ microRNA $\langle /scp \rangle$ 423-5p are associated with 90-day mortality in cardiogenic shock. ESC Heart Failure, 2019, 6, 98-102.	1.4	15
337	Right Ventricular Dysfunction Staging System for Mortality Risk Stratification in Heart Failure with Preserved Ejection Fraction. Journal of Clinical Medicine, 2020, 9, 831.	1.0	15
338	Nepriylisin inhibition, endorphin dynamics, and early symptomatic improvement in heart failure: a pilot study. ESC Heart Failure, 2020, 7, 559-566.	1.4	15
339	Persistent chest pain after recovery of COVID-19: microvascular disease-related angina?. European Heart Journal - Case Reports, 2021, 5, ytab105.	0.3	15
340	Elevated Levels of Plasmin- ± 2 Antiplasmin Complexes in Unstable Angina. Thrombosis and Haemostasis, 1999, 81, 865-868.	1.8	15
341	Interatrial shunting for heart failure: current evidence and future perspectives. EuroIntervention, 2019, 15, 164-171.	1.4	15
342	Circulating levels and prognostic cutoffs of sST2, hs-cTnT, and NT-proBNP in women vs. men with chronic heart failure. ESC Heart Failure, 2022, 9, 2084-2095.	1.4	15

#	ARTICLE	IF	CITATIONS
343	Effects of insulin-like growth factor-I on cultured human coronary artery smooth muscle cells. Growth Hormone and IGF Research, 2003, 13, 246-253.	0.5	14
344	Changes in myocardial electrical impedance in human heart graft rejection. European Journal of Heart Failure, 2008, 10, 594-600.	2.9	14
345	Resumen de estudios clínicos presentados en el Congreso de 2011 de la European Society of Cardiology (27-30 de agosto de 2011, París, Francia). Revista Espanola De Cardiologia, 2011, 64, 1011.e1-1011.e8.	0.6	14
346	Limited Value of Cystatin-C over Estimated Glomerular Filtration Rate for Heart Failure Risk Stratification. PLoS ONE, 2012, 7, e51234.	1.1	14
347	Yin-Yang 1 transcription factor modulates ST2 expression during adverse cardiac remodeling post-myocardial infarction. Journal of Molecular and Cellular Cardiology, 2019, 130, 216-233.	0.9	14
348	Hydrogen- and Methane-Based Breath Testing and Outcomes in Patients With Heart Failure. Journal of Cardiac Failure, 2019, 25, 319-327.	0.7	14
349	Role of PCSK9 in the course of ejection fraction change after ST-segment elevation myocardial infarction: a pilot study. ESC Heart Failure, 2020, 7, 118-123.	1.4	14
350	Short- and Long-Term Mortality Trends in STEMI-Cardiogenic Shock over Three Decades (1989-2018): The Ruti-STEMI-Shock Registry. Journal of Clinical Medicine, 2020, 9, 2398.	1.0	14
351	Rehospitalization burden and morbidity risk in patients with heart failure with mid-range ejection fraction. ESC Heart Failure, 2020, 7, 1007-1014.	1.4	14
352	An outlook on biomarkers in cardiogenic shock. Current Opinion in Critical Care, 2020, 26, 392-397.	1.6	14
353	Mortality trends in an ambulatory multidisciplinary heart failure unit from 2001 to 2018. Scientific Reports, 2021, 11, 732.	1.6	14
354	Long COVID-19 and microvascular disease-related angina. Revista Espanola De Cardiologia (English Ed), 2022, 75, 444-446.	0.4	14
355	Integration of a local into a regional primary angioplasty action plan (the Catalan Codi Infart) Tj ETQq1 1 0.784314 rgBT /Overlock 10 0.8 13	0.8	13
356	Innovación en cardiología: introducción. Revista Espanola De Cardiologia, 2013, 66, 133.	0.6	13
357	Impact of Umbilical Cord Blood-Derived Mesenchymal Stem Cells on Cardiovascular Research. BioMed Research International, 2015, 2015, 1-6.	0.9	13
358	Time-dependent effects of unfractionated heparin in patients with ST-elevation myocardial infarction transferred for primary angioplasty. International Journal of Cardiology, 2015, 198, 70-74.	0.8	13
359	Cinética de la hemoglobina y pronóstico a largo plazo en insuficiencia cardiaca. Revista Espanola De Cardiologia, 2016, 69, 820-826.	0.6	13
360	El consumo máximo de oxígeno predice los ingresos recurrentes por insuficiencia cardiaca con fracción de eyección conservada. Revista Espanola De Cardiologia, 2018, 71, 250-256.	0.6	13

#	ARTICLE	IF	CITATIONS
361	Use of acetazolamide in the treatment of patients with refractory congestive heart failure. <i>Cardiovascular Therapeutics</i> , 2018, 36, e12465.	1.1	13
362	Primary Ventricular Fibrillation in the Primary Percutaneous Coronary Intervention ST-Segment Elevation Myocardial Infarction Era (from the "Codi IAM" Multicenter Registry). <i>American Journal of Cardiology</i> , 2018, 122, 529-536.	0.7	13
363	Elastomeric cardiopatch scaffold for myocardial repair and ventricular support. <i>European Journal of Cardio-thoracic Surgery</i> , 2019, 57, 545-555.	0.6	13
364	Lung Ultrasound for Heart Failure Diagnosis in Primary Care. <i>Journal of Cardiac Failure</i> , 2020, 26, 824-831.	0.7	13
365	Mechanisms governing the therapeutic effect of mesenchymal stromal cell-derived extracellular vesicles: A scoping review of preclinical evidence. <i>Biomedicine and Pharmacotherapy</i> , 2022, 147, 112683.	2.5	13
366	Autoimmunity and Atrioventricular Block of Unknown Etiology in Adults. <i>Journal of the American College of Cardiology</i> , 2014, 63, 1335-1336.	1.2	12
367	Aging and Heart Rate in Heart Failure: Clinical Implications for Long-term Mortality. <i>Mayo Clinic Proceedings</i> , 2015, 90, 765-772.	1.4	12
368	Multi-Biomarker Profiling and Recurrent Hospitalizations in Heart Failure. <i>Frontiers in Cardiovascular Medicine</i> , 2016, 3, 37.	1.1	12
369	Serum neprilysin and recurrent hospitalizations after acute heart failure. <i>International Journal of Cardiology</i> , 2016, 220, 742-744.	0.8	12
370	Wearable vest for pulmonary congestion tracking and prognosis in heart failure: A pilot study. <i>International Journal of Cardiology</i> , 2016, 215, 77-79.	0.8	12
371	First-in-man Safety and Efficacy of the Adipose Graft Transposition Procedure (AGTP) in Patients With a Myocardial Scar. <i>EBioMedicine</i> , 2016, 7, 248-254.	2.7	12
372	Relationship among LRP1 expression, Pyk2 phosphorylation and MMP9 activation in left ventricular remodelling after myocardial infarction. <i>Journal of Cellular and Molecular Medicine</i> , 2017, 21, 1915-1928.	1.6	12
373	Bloodstream Amyloid-beta (1-40) Peptide, Cognition, and Outcomes in Heart Failure. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2017, 70, 924-932.	0.4	12
374	Second-degree interatrial block: Brief review and concept. <i>Annals of Noninvasive Electrocardiology</i> , 2018, 23, e12583.	0.5	12
375	Inspiratory Muscle Training and Functional Electrical Stimulation for Treatment of Heart Failure With Preserved Ejection Fraction: The TRAINING-HF Trial. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2019, 72, 288-297.	0.4	12
376	Differential prognostic impact of type 2 diabetes mellitus in women and men with heart failure with preserved ejection fraction. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2020, 73, 463-470.	0.4	12
377	Soluble Neprilysin and Corin Concentrations in Relation to Clinical Outcome in Chronic Heart Failure. <i>JACC: Heart Failure</i> , 2021, 9, 85-95.	1.9	12
378	Targeting N-Terminal Pro-Brain Natriuretic Peptide in Older Versus Younger Acute Decompensated Heart Failure Patients. <i>JACC: Heart Failure</i> , 2016, 4, 736-745.	1.9	11

#	ARTICLE	IF	CITATIONS
379	Circulating Endothelial Progenitor Cells: Potential Biomarkers for Idiopathic Dilated Cardiomyopathy. <i>Journal of Cardiovascular Translational Research</i> , 2016, 9, 80-84.	1.1	11
380	Peak Exercise Oxygen Uptake Predicts Recurrent Admissions in Heart Failure With Preserved Ejection Fraction. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2018, 71, 250-256.	0.4	11
381	Acute-phase dynamics and prognostic value of growth differentiation factor-15 in ST-elevation myocardial infarction. <i>Clinical Chemistry and Laboratory Medicine</i> , 2019, 57, 1093-1101.	1.4	11
382	Digoxin and prognosis of heart failure in older patients with preserved ejection fraction: Importance of heart rate. Results from an observational and multicenter study. <i>European Journal of Internal Medicine</i> , 2019, 60, 18-23.	1.0	11
383	Renal function dynamics following coadministration of sacubitril/valsartan and empagliflozin in patients with heart failure and type 2 diabetes. <i>ESC Heart Failure</i> , 2020, 7, 3792-3800.	1.4	11
384	Prognostic value of reverse remodelling criteria in heart failure with reduced or mid-range ejection fraction. <i>ESC Heart Failure</i> , 2021, 8, 3014-3025.	1.4	11
385	Effects of empagliflozin on CA125 trajectory in patients with chronic congestive heart failure. <i>International Journal of Cardiology</i> , 2021, 339, 102-105.	0.8	11
386	Midterm Outcomes Following Sutureless and Transcatheter Aortic Valve Replacement in Low-Risk Patients With Aortic Stenosis. <i>Circulation: Cardiovascular Interventions</i> , 2021, 14, e011120.	1.4	11
387	Hypertrophy and inflammation: too much for one heart. <i>European Heart Journal</i> , 2007, 28, 661-663.	1.0	10
388	Summary of the Clinical Studies Reported in the European Society of Cardiology Congress 2010 (August 28-September 1, 2010, Stockholm, Sweden). <i>Revista Espanola De Cardiologia (English Ed)</i> , 2010, 63, 1292-1303.	0.4	10
389	Obesidad y pronóstico a largo plazo en la insuficiencia cardiaca: la paradoja continúa. <i>Revista Espanola De Cardiologia</i> , 2010, 63, 1210-1212.	0.6	10
390	Enfermedades sistémicas y corazón: introducción. <i>Revista Espanola De Cardiologia</i> , 2011, 64, 60-61.	0.6	10
391	Arritmias: Introducción. <i>Revista Espanola De Cardiologia</i> , 2012, 65, 91.	0.6	10
392	Resumen de los ensayos clínicos presentados en las Sesiones Científicas Anuales del American College of Cardiology (Chicago, Illinois, Estados Unidos, 24-27 de marzo de 2012). <i>Revista Espanola De Cardiologia</i> , 2012, 65, 559.e1-559.e8.	0.6	10
393	Resumen de estudios clínicos presentados en el Congreso de 2012 de la Sociedad Europea de Cardiología (25-29 de agosto de 2012, Múnich, Alemania). <i>Revista Espanola De Cardiologia</i> , 2012, 65, 1018.e1-1018.e8.	0.6	10
394	Preclinical Safety Evaluation of Allogeneic Induced Pluripotent Stem Cell-Based Therapy in a Swine Model of Myocardial Infarction. <i>Tissue Engineering - Part C: Methods</i> , 2017, 23, 736-744.	1.1	10
395	Unravelling the effects of mechanical physiological conditioning on cardiac adipose tissue-derived progenitor cells in vitro and in silico. <i>Scientific Reports</i> , 2018, 8, 499.	1.6	10
396	High-sensitivity troponin T in asymptomatic severe aortic stenosis. <i>Biomarkers</i> , 2019, 24, 334-340.	0.9	10

#	ARTICLE	IF	CITATIONS
397	Hyperkalemia in heart failure patients in Spain and its impact on guidelines and recommendations: ESC-EORP-HFA Heart Failure Long-Term Registry. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2020, 73, 313-323.	0.4	10
398	Colchicine for the treatment of coronary artery disease. <i>Trends in Cardiovascular Medicine</i> , 2021, 31, 497-504.	2.3	10
399	Relationship Between Bioimpedance Vector Displacement and Renal Function After a Marathon in Non-elite Runners. <i>Frontiers in Physiology</i> , 2020, 11, 352.	1.3	10
400	Atypical advanced interatrial block due to giant atrial lipoma. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2021, 44, 737-739.	0.5	10
401	Pre-analytical considerations in biomarker research: focus on cardiovascular disease. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, 59, 1747-1760.	1.4	10
402	The "Peptide for Life"™ Initiative: a call for action to provide equal access to the use of natriuretic peptides in the diagnosis of acute heart failure across Europe. <i>European Journal of Heart Failure</i> , 2021, 23, 1432-1436.	2.9	10
403	Prognostic value of NT-proBNP and CA125 across glomerular filtration rate categories in acute heart failure. <i>European Journal of Internal Medicine</i> , 2022, 95, 67-73.	1.0	10
404	Use of intravenous iron in patients with iron deficiency and chronic heart failure: Real-world evidence. <i>European Journal of Internal Medicine</i> , 2020, 80, 91-98.	1.0	10
405	Advanced remote care for heart failure in times of COVID-19 using an implantable pulmonary artery pressure sensor: the new normal. <i>European Heart Journal Supplements</i> , 2020, 22, P29-P32.	0.0	10
406	The utility of stent enhancement to guide percutaneous coronary intervention for bifurcation lesions. <i>EuroIntervention</i> , 2013, 9, 968-974.	1.4	10
407	B-type natriuretic peptide release in the coronary effluent after acute transient ischaemia in humans. <i>Heart</i> , 2007, 93, 1077-1080.	1.2	9
408	Nueva etapa editorial y nuevos proyectos. <i>Revista Espanola De Cardiologia</i> , 2010, 63, 865-868.	0.6	9
409	Resumen anual año 2010: datos bibliométricos, actividades y nueva producción de la Revista. <i>Revista Espanola De Cardiologia</i> , 2010, 63, 1501-1509.	0.6	9
410	Resumen de estudios clínicos presentados en el Congreso de 2013 de la Sociedad Europea de Cardiología (31 de agosto-4 de septiembre de 2013, Ámsterdam, Países Bajos). <i>Revista Espanola De Cardiologia</i> , 2013, 66, 879.e1-879.e9.	0.6	9
411	Resumen de los ensayos clínicos presentados en las Sesiones Científicas Anuales del American College of Cardiology (San Francisco, California, Estados Unidos, 8-12 de marzo de 2013). <i>Revista Espanola De Cardiologia</i> , 2013, 66, 482.e1-482.e8.	0.6	9
412	Real-life use of the polypill components (ASA+ACEI+statins) after an acute coronary syndrome and long-term mortality. <i>International Journal of Cardiology</i> , 2014, 177, 209-210.	0.8	9
413	Peptidos natriuréticos: consenso y uso necesarios. <i>Revista Espanola De Cardiologia</i> , 2016, 69, 817-819.	0.6	9
414	The real-life value of ST2 monitoring during heart failure decompensation: impact on long-term readmission and mortality. <i>Biomarkers</i> , 2016, 21, 225-232.	0.9	9

#	ARTICLE	IF	CITATIONS
415	Naming and classifying old and new ECG phenomena. <i>Cmaj</i> , 2016, 188, 485-486.	0.9	9
416	Extracellular vesicles do not contribute to higher circulating levels of soluble LRP1 in idiopathic dilated cardiomyopathy. <i>Journal of Cellular and Molecular Medicine</i> , 2017, 21, 3000-3009.	1.6	9
417	Rationale and design of a multicentre, prospective, randomised, controlled clinical trial to evaluate the efficacy of the adipose graft transposition procedure in patients with a myocardial scar: the AGTP II trial. <i>BMJ Open</i> , 2017, 7, e017187.	0.8	9
418	The misperception of "stable" heart failure. <i>European Journal of Heart Failure</i> , 2018, 20, 1375-1378.	2.9	9
419	Determination of HLA-A, -B, -C, -DRB1 and -DQB1 allele and haplotype frequencies in heart failure patients. <i>ESC Heart Failure</i> , 2019, 6, 388-395.	1.4	9
420	The role of N-terminal pro-B-type natriuretic peptide in prognostic evaluation of heart failure. <i>Journal of the Chinese Medical Association</i> , 2019, 82, 447-451.	0.6	9
421	Long-term LVEF trajectories in patients with type 2 diabetes and heart failure: diabetic cardiomyopathy may underlie functional decline. <i>Cardiovascular Diabetology</i> , 2020, 19, 38.	2.7	9
422	Soluble ST2 and Diuretic Efficiency in Acute Heart Failure and Concomitant Renal Dysfunction. <i>Journal of Cardiac Failure</i> , 2021, 27, 427-434.	0.7	9
423	Thirst and factors associated with frequent thirst in patients with heart failure in Spain. <i>Heart and Lung: Journal of Acute and Critical Care</i> , 2021, 50, 86-91.	0.8	9
424	Iron deficiency and short-term adverse events in patients with decompensated heart failure. <i>Clinical Research in Cardiology</i> , 2021, 110, 1292-1298.	1.5	9
425	Cambio en la causa de muerte e influencia de la mejora terapéutica con el tiempo en pacientes con insuficiencia cardiaca y fracción de eyección reducida. <i>Revista Espanola De Cardiologia</i> , 2020, 73, 561-568.	0.6	9
426	Evolution of amino-terminal Pro-B type natriuretic peptide testing in heart failure. <i>Drug News and Perspectives</i> , 2009, 22, 267.	1.9	9
427	Destination Therapy with Left Ventricular Assist Devices in Non-transplant Centres: The Time is Right. <i>European Cardiology Review</i> , 2020, 15, e19.	0.7	9
428	Can Natriuretic Peptides be Used to Guide Therapy?. <i>Electronic Journal of the International Federation of Clinical Chemistry and Laboratory Medicine</i> , 2016, 27, 208-16.	0.7	9
429	Safety and efficacy of transradial access in coronary angiography: 8-year experience. <i>Journal of Invasive Cardiology</i> , 2012, 24, 346-51.	0.4	9
430	Revista Española de Cardiología, siguiendo el pulso de la era digital. <i>Revista Espanola De Cardiologia</i> , 2013, 66, 996-998.	0.6	8
431	Advanced interatrial block: a well-defined electrocardiographic pattern with clinical arrhythmological implications. <i>Europace</i> , 2013, 15, 1822-1822.	0.7	8
432	Risk Prediction Tools in Patients With Heart Failure. <i>JACC: Heart Failure</i> , 2015, 3, 267.	1.9	8

#	ARTICLE	IF	CITATIONS
433	A method to adapt thoracic impedance based on chest geometry and composition to assess congestion in heart failure patients. <i>Medical Engineering and Physics</i> , 2016, 38, 538-546.	0.8	8
434	Neprilisina: indicaciones, expectativas y retos. <i>Revista Espanola De Cardiologia</i> , 2016, 69, 647-649.	0.6	8
435	A DAG-based comparison of interventional effect underestimation between composite endpoint and multi-state analysis in cardiovascular trials. <i>BMC Medical Research Methodology</i> , 2017, 17, 92.	1.4	8
436	Î2-Blocker treatment and prognosis in acute coronary syndrome associated with cocaine consumption: The RUTI-Cocaine Study. <i>International Journal of Cardiology</i> , 2018, 260, 7-10.	0.8	8
437	Circulating monocyte subsets and heart failure prognosis. <i>PLoS ONE</i> , 2018, 13, e0204074.	1.1	8
438	Spotlight on epigenetic reprogramming in cardiac regeneration. <i>Seminars in Cell and Developmental Biology</i> , 2020, 97, 26-37.	2.3	8
439	Intracoronary Delivery of Porcine Cardiac Progenitor Cells Overexpressing IGF-1 and HGF in a Pig Model of Sub-Acute Myocardial Infarction. <i>Cells</i> , 2021, 10, 2571.	1.8	8
440	Inspiratory Muscle Function and Exercise Capacity in Patients With Heart Failure With Preserved Ejection Fraction. <i>Journal of Cardiac Failure</i> , 2017, 23, 480-484.	0.7	8
441	La fibrosis intersticial miocárdica en la era de la medicina de precisión. El fenotipado basado en biomarcadores para un tratamiento personalizado. <i>Revista Espanola De Cardiologia</i> , 2020, 73, 248-254.	0.6	8
442	Growth differentiation factor 15 and early prognosis after out-of-hospital cardiac arrest. <i>Annals of Intensive Care</i> , 2019, 9, 119.	2.2	8
443	Prognostic value of increased carbohydrate antigen in patients with heart failure. <i>World Journal of Cardiology</i> , 2014, 6, 205.	0.5	8
444	Right ventricular function and iron deficiency in acute heart failure. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021, 10, 406-414.	0.4	8
445	Coronary smooth muscle reactivity to muscarinic stimulation after ischemia-reperfusion in porcine myocardial infarction. <i>Journal of Applied Physiology</i> , 2003, 95, 81-88.	1.2	7
446	Análisis de la demanda telefónica en una unidad de insuficiencia cardiaca: motivos de consulta y utilización de recursos. <i>Revista Espanola De Cardiologia</i> , 2013, 66, 914-915.	0.6	7
447	New insights into lipid raft function regulating myocardial vascularization competency in human idiopathic dilated cardiomyopathy. <i>Atherosclerosis</i> , 2013, 230, 354-364.	0.4	7
448	Microwave spectrometry for the evaluation of the structural integrity of metallic stents. <i>Medical Physics</i> , 2014, 41, 041902.	1.6	7
449	Cardiac Tissue Engineering. <i>Journal of the American College of Cardiology</i> , 2016, 68, 724-726.	1.2	7
450	Neprilysin: Indications, Expectations, and Challenges. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2016, 69, 647-649.	0.4	7

#	ARTICLE	IF	CITATIONS
451	Hemoglobin Kinetics and Long-term Prognosis in Heart Failure. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2016, 69, 820-826.	0.4	7
452	Evaluación de los algoritmos de Smith para el diagnóstico de infarto agudo de miocardio en presencia de bloqueo de rama izquierda del haz de His. <i>Revista Espanola De Cardiologia</i> , 2017, 70, 559-566.	0.6	7
453	Compelling Benefit of Soluble Suppression of Tumorigenicity-2 in Post-Myocardial Infarction Estimation of Risk: The Time Is Right for Its Routine Use in the Clinic. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	7
454	Conservative management in very elderly patients with severe aortic stenosis: Time to change?. <i>Journal of Cardiology</i> , 2017, 69, 883-887.	0.8	7
455	Benzodiazepine Use and Long-Term Mortality in Real-Life Chronic Heart Failure Outpatients: A Cohort Analysis. <i>Psychotherapy and Psychosomatics</i> , 2018, 87, 372-374.	4.0	7
456	What every clinician should know about Bayés syndrome. <i>Revista Espanola De Cardiologia (English Ed)</i> 10.4374/journal.ifc.100000	0.4	7
457	Relation of Interatrial Block to Cognitive Impairment in Patients ≥70 Years of Age (From the CAMBIAD) 10.1016/j.amjcard.2017.07.011	0.7	7
458	Low-density lipoprotein receptor-related protein 1 deficiency in cardiomyocytes reduces susceptibility to insulin resistance and obesity. <i>Metabolism: Clinical and Experimental</i> , 2020, 106, 154191.	1.5	7
459	Transitioning From Preclinical Evidence to Advanced Therapy Medicinal Product: A Spanish Experience. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 604434.	1.1	7
460	Thirst distress in outpatients with heart failure in a Mediterranean zone of Spain. <i>ESC Heart Failure</i> , 2021, 8, 2492-2501.	1.4	7
461	Long-term antibiotic therapy in patients with surgery-indicated not undergoing surgery infective endocarditis. <i>Cardiology Journal</i> , 2021, 28, 566-578.	0.5	7
462	Marathon Running Increases Synthesis and Decreases Catabolism of Joint Cartilage Type II Collagen Accompanied by High-Energy Demands and an Inflammatory Reaction. <i>Frontiers in Physiology</i> , 2021, 12, 722718.	1.3	7
463	Lung ultrasound in outpatients with heart failure: the wet-dry HF study. <i>ESC Heart Failure</i> , 2021, 8, 4506-4516.	1.4	7
464	Sex-Related Differences in Mortality Following Admission for Acute Heart Failure Across the Left Ventricular Ejection Fraction Spectrum. <i>Journal of the American Heart Association</i> , 2022, 11, e022404.	1.6	7
465	Carbohydrate antigen 125 and risk of heart failure readmissions in patients with heart failure and preserved ejection fraction. <i>Scientific Reports</i> , 2022, 12, 1344.	1.6	7
466	Systemic Diseases and the Cardiovascular System: Introduction. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2011, 64, 60-61.	0.4	6
467	Resumen de los ensayos clínicos presentados en las Sesiones Científicas Anuales de la American Heart Association (Orlando, Estados Unidos, 12-16 de noviembre de 2011). <i>Revista Espanola De Cardiologia</i> , 2012, 65, 71.e1-71.e9.	0.6	6
468	Resumen anual y novedades del año 2012 en REVISTA ESPAÑOLA DE CARDIOLOGÍA. <i>Revista Espanola De Cardiologia</i> , 2013, 66, 231-240.	0.6	6

#	ARTICLE	IF	CITATIONS
469	Quality and exploitation of umbilical cord blood for cell therapy: Are we beyond our capabilities?. <i>Developmental Dynamics</i> , 2016, 245, 710-717.	0.8	6
470	Assessment of respiratory flow cycle morphology in patients with chronic heart failure. <i>Medical and Biological Engineering and Computing</i> , 2017, 55, 245-255.	1.6	6
471	Telomere attrition in heart failure: a flow-FISH longitudinal analysis of circulating monocytes. <i>Journal of Translational Medicine</i> , 2018, 16, 35.	1.8	6
472	Pulmonary vascular resistance versus pulmonary artery pressure for predicting right ventricular remodeling and functional tricuspid regurgitation. <i>Echocardiography</i> , 2018, 35, 1736-1745.	0.3	6
473	Simultaneous Electrical and Mechanical Stimulation to Enhance Cells' Cardiomyogenic Potential. <i>Journal of Visualized Experiments</i> , 2019, , .	0.2	6
474	Early Sacubitril/Valsartan-driven Benefit on Exercise Capacity in Heart Failure With Reduced Ejection Fraction: A Pilot Study. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2019, 72, 167-169.	0.4	6
475	Short- and long-term mortality in patients with left-sided infective endocarditis not undergoing surgery despite indication. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2020, 73, 734-740.	0.4	6
476	The pre-HFpEF stage: a new entity that requires proper phenotyping for better management. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 935-936.	0.8	6
477	Decellularized pericardial extracellular matrix: The preferred porous scaffold for regenerative medicine. <i>Xenotransplantation</i> , 2020, 27, e12580.	1.6	6
478	Changes in causes of death and influence of therapeutic improvement over time in patients with heart failure and reduced ejection fraction. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2020, 73, 561-568.	0.4	6
479	Transition to heart failure in hypertension: going to the heart of the matter. <i>European Heart Journal</i> , 2022, 43, 3332-3334.	1.0	6
480	Atrial Mitral and Tricuspid Regurgitation: Sex Matters. A Call for Action to Unravel the Differences Between Women and Men. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	6
481	Characterization of periodic and non-periodic breathing pattern in chronic heart failure patients. , 2008, 2008, 3227-30.		5
482	Fetal-maternal interface: A chronicle of allogeneic coexistence. <i>Chimerism</i> , 2012, 3, 18-23.	0.7	5
483	Revista Española de Cardiología: Keeping Its Finger on the Pulse of the Digital Age. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2013, 66, 996-998.	0.4	5
484	Formación médica continuada: un objetivo prioritario en Revista Española de Cardiología. <i>Revista Espanola De Cardiologia</i> , 2014, 67, 1068-1073.	0.6	5
485	Síndromes coronarios agudos: nuevas estrategias de diagnóstico y tratamiento. <i>Revista Espanola De Cardiologia</i> , 2014, 67, 138.	0.6	5
486	Resumen de estudios clínicos presentados en el Congreso de 2014 de la Sociedad Europea de Cardiología (30 de agosto-3 de septiembre de 2014, Barcelona, España). <i>Revista Espanola De Cardiologia</i> , 2014, 67, 912.e1-912.e10.	0.6	5

#	ARTICLE	IF	CITATIONS
487	Putting Together the Pieces of the Natriuretic Peptide Puzzle —. JACC: Heart Failure, 2016, 4, 670-673.	1.9	5
488	Síndrome de Bayés. Revista Espanola De Cardiologia, 2016, 69, 439.	0.6	5
489	Assessment of Smith Algorithms for the Diagnosis of Acute Myocardial Infarction in the Presence of Left Bundle Branch Block. Revista Espanola De Cardiologia (English Ed), 2017, 70, 559-566.	0.4	5
490	Carbohydrate Antigen-125 in Heart Failure. JACC: Heart Failure, 2018, 6, 441-442.	1.9	5
491	No need for urgent revisiting of kalaemia levels in guidelines despite use of mineralocorticoid receptor antagonists: bring in more evidence. European Journal of Heart Failure, 2018, 20, 1252-1254.	2.9	5
492	External Validation of the ELAN-HF Score, Predicting 6-Month All-Cause Mortality in Patients Hospitalized for Acute Decompensated Heart Failure. Journal of the American Heart Association, 2019, 8, e010309.	1.6	5
493	Liquid Biopsy and eHealth in Heart Failure. Journal of the American College of Cardiology, 2019, 73, 2206-2208.	1.2	5
494	Effects of a polysaccharide-based multi-ingredient supplement on salivary immunity in non-elite marathon runners. Journal of the International Society of Sports Nutrition, 2019, 16, 14.	1.7	5
495	Dinámica de microARN circulantes en pacientes con infarto agudo de miocardio con elevación del segmento ST con shock cardiogénico. Revista Espanola De Cardiologia, 2019, 72, 783-785.	0.6	5
496	The impact of frailty in aortic valve surgery. BMC Geriatrics, 2020, 20, 426.	1.1	5
497	Early Spot Urinary Sodium and Diuretic Efficiency in Acute Heart Failure and Concomitant Renal Dysfunction. CardioRenal Medicine, 2020, 10, 362-372.	0.7	5
498	Clinical profile and 1-year clinical outcomes of super elderly patients admitted with acute heart failure. European Journal of Internal Medicine, 2020, 81, 78-82.	1.0	5
499	Cardiorenal interaction and heart failure outcomes. A role for insulin-like growth factor binding protein 2?. Revista Espanola De Cardiologia (English Ed), 2020, 73, 835-843.	0.4	5
500	Prevalence of risk of thrombosis and of bleeding and antithrombotic treatment in patients with heart failure. European Journal of Heart Failure, 2020, 22, 906-910.	2.9	5
501	Transitioning from a coronary to a critical cardiovascular care unit: trends over the past three decades. European Heart Journal: Acute Cardiovascular Care, 2021, 10, 437-444.	0.4	5
502	Efecto pronóstico diferencial de la diabetes mellitus tipo 2 en mujeres y varones con insuficiencia cardíaca y fracción de eyección conservada. Revista Espanola De Cardiologia, 2020, 73, 463-470.	0.6	5
503	Short-Term Changes in Left and Right Ventricular Cardiac Magnetic Resonance Feature Tracking Strain Following Ferric Carboxymaltose in Patients With Heart Failure: A Substudy of the MyocardialIRON Trial. Journal of the American Heart Association, 2022, 11, e022214.	1.6	5
504	â€Peptide for Life™ in primary care: work in progress. European Heart Journal, 2021, , .	1.0	5

#	ARTICLE	IF	CITATIONS
505	Non-STEMI vs. STEMI Cardiogenic Shock: Clinical Profile and Long-Term Outcomes. <i>Journal of Clinical Medicine</i> , 2022, 11, 3558.	1.0	5
506	Annual Summary 2010: Bibliometric Data, Activities, and New Production of the Journal. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2010, 63, 1501-1509.	0.4	4
507	New Statistical Methods in Cardiovascular Research. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2011, 64, 499-500.	0.4	4
508	2012 Annual Summary and New Projects in <i>Revista Espanola de Cardiologia</i> . <i>Revista Espanola De Cardiologia (English Ed)</i> , 2013, 66, 231-240.	0.4	4
509	Statins in heart failure: not yet the end of the story?. <i>European Journal of Heart Failure</i> , 2013, 15, 708-709.	2.9	4
510	Acute Coronary Syndromes. New Diagnostic Strategies and Treatment. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2014, 67, 138.	0.4	4
511	Cardiorespiratory and cardiovascular interactions in cardiomyopathy patients using joint symbolic dynamic analysis. , 2015, 2015, 306-9.		4
512	Validación de la Barcelona Bio-Heart Failure Risk Calculator en una cohorte de Boston. <i>Revista Espanola De Cardiologia</i> , 2015, 68, 80-81.	0.6	4
513	The International ST2 Consensus Panel: Introduction. <i>American Journal of Cardiology</i> , 2015, 115, 1B-2B.	0.7	4
514	Destino de los artículos originales rechazados en <i>Revista Espanola de Cardiologia</i> . <i>Revista Espanola De Cardiologia</i> , 2015, 68, 263-264.	0.6	4
515	Soluble neprilysin does not correlate with outcome in heart failure with preserved ejection fraction?. <i>European Journal of Heart Failure</i> , 2016, 18, 576-576.	2.9	4
516	Bayés-Sá™ Syndrome. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2016, 69, 439.	0.4	4
517	Worsening Renal Function in Acute Decompensated Heart Failure. <i>JACC: Heart Failure</i> , 2016, 4, 232-233.	1.9	4
518	Characterization and classification of patients with different levels of cardiac death risk by using Poincaré plot analysis. , 2017, 2017, 1332-1335.		4
519	Asymptomatic severe aortic stenosis: biomarkers are welcome. <i>Heart</i> , 2018, 105, heartjnl-2018-314122.	1.2	4
520	The Barcelona Bio-HF Calculator. <i>JACC: Heart Failure</i> , 2018, 6, 808-810.	1.9	4
521	Razón internacional normalizada y mortalidad de los pacientes con insuficiencia cardiaca y fibrilación auricular tratados con antagonistas de la vitamina K. <i>Revista Espanola De Cardiologia</i> , 2019, 72, 616-624.	0.6	4
522	Resonance-Based Microwave Technique for Body Implant Sensing. <i>Sensors</i> , 2019, 19, 4828.	2.1	4

#	ARTICLE	IF	CITATIONS
523	Old teaching tools should not be forgotten: The value of the Lewis ladder diagram in understanding bigeminal rhythms. <i>Annals of Noninvasive Electrocardiology</i> , 2019, 24, e12685.	0.5	4
524	Woven Coronary Disease. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e008087.	1.4	4
525	Magnetic resonance microscopy and correlative histopathology of the infarcted heart. <i>Scientific Reports</i> , 2019, 9, 20017.	1.6	4
526	Efecto inicial del sacubitrilo-valsartán sobre la capacidad funcional en pacientes con insuficiencia cardíaca con fracción de eyección reducida: estudio piloto. <i>Revista Espanola De Cardiología</i> , 2019, 72, 167-169.	0.6	4
527	Myocardial interstitial fibrosis in the era of precision medicine. Biomarker-based phenotyping for a personalized treatment. <i>Revista Espanola De Cardiología (English Ed)</i> , 2020, 73, 248-254.	0.4	4
528	Chronotropic Incompetence Predicts Distance Walked in Six-Minute Walk Test in Heart Failure With Preserved Ejection Fraction. <i>Journal of Cardiac Failure</i> , 2020, 26, 1024-1025.	0.7	4
529	Prognostic value of lung ultrasound in chronic stable ambulatory heart failure patients. <i>Revista Espanola De Cardiología (English Ed)</i> , 2021, 74, 862-869.	0.4	4
530	Sacubitril/Valsartan as Antifibrotic Drug. <i>Journal of the American College of Cardiology</i> , 2020, 76, 515-517.	1.2	4
531	Early urinary sodium trajectory and risk of adverse outcomes in acute heart failure and renal dysfunction. <i>Revista Espanola De Cardiología (English Ed)</i> , 2021, 74, 616-623.	0.4	4
532	Longitudinal strain in remote non-infarcted myocardium by tissue tracking CMR: characterization, dynamics, structural and prognostic implications. <i>International Journal of Cardiovascular Imaging</i> , 2021, 37, 241-253.	0.7	4
533	Heart failure is ejection fraction in motion. <i>European Journal of Heart Failure</i> , 2021, 23, 564-566.	2.9	4
534	Comparison between CA125 and NT-proBNP for evaluating congestion in acute heart failure. <i>Medicina Clínica (English Edition)</i> , 2021, 156, 589-594.	0.1	4
535	Clinical utility of antigen carbohydrate 125 for planning the optimal length of stay in acute heart failure. <i>European Journal of Internal Medicine</i> , 2021, 92, 94-99.	1.0	4
536	Unplanned redundant publication: a consequence of too many cardiovascular journals?. <i>EuroIntervention</i> , 2010, 6, 179-181.	1.4	4
537	Cause of Death in Heart Failure Based on Etiology: Long-Term Cohort Study of All-Cause and Cardiovascular Mortality. <i>Journal of Clinical Medicine</i> , 2022, 11, 784.	1.0	4
538	Dysglycaemia and high natriuretic peptides: the prelude to heart failure. <i>European Journal of Heart Failure</i> , 2022, 24, 254-256.	2.9	4
539	Cardiac protection by pirfenidone after myocardial infarction: a bioinformatic analysis. <i>Scientific Reports</i> , 2022, 12, 4691.	1.6	4
540	Clinical translation of mesenchymal stromal cell extracellular vesicles: Considerations on scientific rationale and production requisites. <i>Journal of Cellular and Molecular Medicine</i> , 2022, 26, 937-939.	1.6	4

#	ARTICLE	IF	CITATIONS
541	Fulminant myocarditis in adults: a narrative review.. Journal of Geriatric Cardiology, 2022, 19, 137-151.	0.2	4
542	Nutritional Status According to the GLIM Criteria in Patients with Chronic Heart Failure: Association with Prognosis. Nutrients, 2022, 14, 2244.	1.7	4
543	A Fibrosis Biomarker Early Predicts Cardiotoxicity Due to Anthracycline-Based Breast Cancer Chemotherapy. Cancers, 2022, 14, 2941.	1.7	4
544	Gene therapy for myocardial angiogenesis: Has it come of age?. Current Atherosclerosis Reports, 2000, 2, 373-379.	2.0	3
545	The Efficacy of Colchicine in the Treatment of Recurrent Pericarditis Related to Postcardiac Injury (Postpericardiectomy and Postinfarcted) Syndrome: A Multicenter Analysis. Cardiology, 2004, 4, 141-144.	0.3	3
546	Comment on "Electrocardiographic bioelectrical impedance vector analysis of value in the elderly with malnutrition and impaired functionality". Nutrition, 2009, 25, 370-371.	1.1	3
547	Obesity and Long-Term Prognosis in Heart Failure: the Paradox Persists. Revista Espanola De Cardiologia (English Ed), 2010, 63, 1210-1211.	0.4	3
548	2011 Annual Summary. Another Meeting With Our Readers. Revista Espanola De Cardiologia (English Ed) 0.4 3	0.4	3
549	CardioPulse Articles. European Heart Journal, 2012, 33, 2883-2891.	1.0	3
550	Desnutrición y pronóstico en insuficiencia cardiaca. Revista Espanola De Cardiologia, 2012, 65, 196-197.	0.6	3
551	Spironolactone in mild chronic heart failure: Insights from a propensity-matched analysis of the MUSIC study cohort. International Journal of Cardiology, 2013, 168, 4525-4527.	0.8	3
552	Chronobiology of Death in Heart Failure. Revista Espanola De Cardiologia (English Ed), 2014, 67, 387-393.	0.4	3
553	To the Editor "Interatrial block and atrial fibrillation: Invasive and noninvasive measurements may help to define the syndrome. Heart Rhythm, 2014, 11, e197-e198.	0.3	3
554	Validation of the Barcelona Bio-Heart Failure Risk Calculator in a Cohort From Boston. Revista Espanola De Cardiologia (English Ed), 2015, 68, 80-81.	0.4	3
555	Brilliant violet fluorochromes in simultaneous multicolor flow cytometry "fluorescence in situ hybridization measurement of monocyte subsets and telomere length in heart failure. Laboratory Investigation, 2016, 96, 1223-1230.	1.7	3
556	Analysis of blood pressure signal in patients with different ventricular ejection fraction using linear and non-linear methods. , 2016, 2016, 2700-2703.		3
557	Revista Española de Cardiología: Current Position and Future Directions. Revista Espanola De Cardiologia (English Ed), 2016, 69, 327-336.	0.4	3
558	Natriuretic Peptides: Consensus Call for Use. Revista Espanola De Cardiologia (English Ed), 2016, 69, 817-819.	0.4	3

#	ARTICLE	IF	CITATIONS
559	Biotherapies and biomarkers for cardiovascular diseases. <i>European Heart Journal</i> , 2017, 38, 1784-1786.	1.0	3
560	Myocardial healing using cardiac fat. <i>Expert Review of Cardiovascular Therapy</i> , 2018, 16, 305-311.	0.6	3
561	Iron status measurement in routine heart failure assessment: a call for action. <i>European Journal of Heart Failure</i> , 2018, 20, 123-124.	2.9	3
562	Intermediate Care Unit After Cardiac Surgery: Impact on Length of Stay and Outcomes. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2018, 71, 638-642.	0.4	3
563	Trends in prevalence and outcomes of acute coronary syndrome associated with cocaine consumption: The RUTI-cocaine study. <i>International Journal of Cardiology</i> , 2019, 283, 23-27.	0.8	3
564	Circulating MiRNA Dynamics in ST-Segment Elevation Myocardial Infarction-driven Cardiogenic Shock. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2019, 72, 783-786.	0.4	3
565	Denervaci3n renal para el tratamiento de la hipertensi3n arterial resistente en Espa1a. <i>Registro Flex-Spyral. Revista Espanola De Cardiologia</i> , 2020, 73, 615-622.	0.6	3
566	Benefit of primary percutaneous coronary interventions in the elderly with ST segment elevation myocardial infarction. <i>Open Heart</i> , 2020, 7, e001169.	0.9	3
567	Macronutrient and mineral intake effects on racing time and cardiovascular health in non-elite marathon runners. <i>Nutrition</i> , 2020, 78, 110806.	1.1	3
568	Optimal carbohydrate antigen 125 cutpoint for identifying low-risk patients after admission for acute heart failure. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2021, , .	0.4	3
569	Right Heart Dysfunction and Readmission Risk Across Left Ventricular Ejection Fraction Status in Patients With Acute Heart Failure. <i>Journal of Cardiac Failure</i> , 2021, 27, 1090-1098.	0.7	3
570	Galectina-3 circulante tras el trasplante cardiaco: din1mica a largo plazo y valor pron1stico. <i>Revista Espanola De Cardiologia</i> , 2019, 72, 899-906.	0.6	3
571	Highlights of the 2016 European Society of Cardiology Guidelines on Heart Failure. <i>European Cardiology Review</i> , 2017, 12, 76.	0.7	3
572	Lung ultrasound and biomarkers in primary care: Partners for a better management of patients with heart failure?. <i>Journal of Circulating Biomarkers</i> , 2020, 9, 8-12.	0.8	3
573	Prevalence and factors associated with atrial mitral and tricuspid regurgitation in patients with atrial fibrillation. <i>Echocardiography</i> , 2021, 38, 2043-2051.	0.3	3
574	Mortality Risk Prediction Dynamics After Heart Failure Treatment Optimization: Repeat Risk Assessment Using Online Risk Calculators. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 836451.	1.1	3
575	New approaches to the pharmacological treatment of angina. <i>Current Opinion in Pharmacology</i> , 2001, 1, 151-158.	1.7	2
576	Reply: Does the adenosine A2A receptor stimulate the ryanodine receptor?. <i>Cardiovascular Research</i> , 2007, 73, 249-250.	1.8	2

#	ARTICLE	IF	CITATIONS
577	Analysis of Reperfusion Delay in Patients With Acute Myocardial Infarction Treated With Primary Angioplasty Based on First Medical Contact and Time of Presentation. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2011, 64, 476-483.	0.4	2
578	From Atrial Fibrillation to Ventricular Fibrillation and Back. <i>Circulation</i> , 2015, 132, 2035-2036.	1.6	2
579	Concentraciones plasmáticas de neprilisina: un nuevo marcador pronóstico en la insuficiencia cardiaca. <i>Revista Espanola De Cardiologia</i> , 2016, 69, 535-536.	0.6	2
580	Potential role for clinical calibration to increase engagement with and application of home telemonitoring: a report from the HeartCycle programme. <i>ESC Heart Failure</i> , 2017, 4, 66-70.	1.4	2
581	Minimally Invasive Adipose Graft Transposition Procedure. <i>Journal of Cardiovascular Translational Research</i> , 2017, 10, 66-68.	1.1	2
582	When the VEST Does Not Fit. <i>Circulation: Heart Failure</i> , 2018, 11, e005116.	1.6	2
583	Impact of a stent for life™ initiative on post-ST elevation myocardial infarction heart failure: a 15-year heart failure clinic experience. <i>ESC Heart Failure</i> , 2018, 5, 101-105.	1.4	2
584	Heart Rate in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2018, 6, 350-351.	1.9	2
585	Una intervención precoz para reducir reingresos a los 30 días en pacientes ancianos frágiles con insuficiencia cardiaca mantiene su beneficio al año. <i>Revista Espanola De Cardiologia</i> , 2019, 72, 261-263.	0.6	2
586	Mortality and Heart Failure Hospitalizations. The Need for an Exhaustive, Official, and Standardized Registry. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2019, 72, 988-990.	0.4	2
587	Step by Step Toward Biomarker-Based Precision Medicine in Heart Failure. <i>Clinical Chemistry</i> , 2019, 65, 1187-1189.	1.5	2
588	Circulating Galectin-3 Following Heart Transplant: Long-term Dynamics and Prognostic Value. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2019, 72, 899-906.	0.4	2
589	Carbohydrate antigen 125 in heart failure. A New era in the monitoring and control of treatment. <i>Medicina Clínica (English Edition)</i> , 2019, 152, 266-273.	0.1	2
590	Heart-Lung-Muscle Anti-SAE Syndrome: An Atypical Severe Combination. <i>Journal of Clinical Medicine</i> , 2019, 8, 20.	1.0	2
591	Renal denervation for the treatment of resistant hypertension in Spain. The Flex-Spyral Registry. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2020, 73, 615-622.	0.4	2
592	Biomarker-guided management in acute heart failure: is there light at the end of the tunnel?. <i>European Journal of Heart Failure</i> , 2020, 22, 276-278.	2.9	2
593	Effect of insulin on readmission for heart failure following a hospitalization for acute heart failure. <i>ESC Heart Failure</i> , 2020, 7, 3320-3328.	1.4	2
594	Consenso de expertos sobre la insuficiencia cardiaca con fracción de eyección reducida: más allá de las guías. <i>Revista Espanola De Cardiologia Suplementos</i> , 2020, 20, 1-46.	0.2	2

#	ARTICLE	IF	CITATIONS
595	Overlapping Effects of miR-21 Inhibition and Drugs for Idiopathic Pulmonary Fibrosis: Rationale for Repurposing Nintedanib as a Novel Treatment for Ischemia/Reperfusion Injury. <i>Journal of Cardiovascular Pharmacology</i> , 2021, 77, 332-333.	0.8	2
596	The influence of sex and body mass index on the association between soluble neprilysin and risk of heart failure hospitalizations. <i>Scientific Reports</i> , 2021, 11, 5940.	1.6	2
597	Editorial: The Role of Sex in Heart Failure and Transplantation. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 690438.	1.1	2
598	Trayectoria precoz del sodio urinario y riesgo de eventos adversos en insuficiencia cardiaca aguda y disfunci3n renal. <i>Revista Espanola De Cardiologia</i> , 2021, 74, 616-623.	0.6	2
599	Usefulness of cardiac screening in patients with systemic lupus erythematosus and anti-Ro/SSA antibodies. <i>Lupus</i> , 2021, 30, 1596-1602.	0.8	2
600	Mortalidad y reingresos por insuficiencia cardiaca: la necesidad de un registro oficial completo, abierto y homologable. <i>Revista Espanola De Cardiologia</i> , 2019, 72, 988-990.	0.6	2
601	Contemporary Yield of 24-hour Holter Monitoring: Role of Inter-Atrial Block Recognition. <i>Journal of Atrial Fibrillation</i> , 2019, 12, 2225.	0.5	2
602	Clinical Determinants and Prognosis of Left Ventricular Reverse Remodelling in Non-Ischemic Dilated Cardiomyopathy. <i>Journal of Cardiovascular Development and Disease</i> , 2022, 9, 20.	0.8	2
603	Circulating linoleic acid at the time of myocardial infarction and risk of primary ventricular fibrillation. <i>Scientific Reports</i> , 2022, 12, 4377.	1.6	2
604	Urinary NGAL in acute heart failure revisited: the game is not over yet. <i>International Journal of Cardiology</i> , 2022, 357, 113-114.	0.8	2
605	Incidence, predictors and prognostic value of permanent pacemaker implantation following sutureless valve implantation in low-risk aortic stenosis patients. <i>European Journal of Cardio-thoracic Surgery</i> , 2022, 62, .	0.6	2
606	Detection and Quantification of Myocardial Fibrosis in Hypertrophic Cardiomyopathy by Contrast-Enhanced Cardiovascular Magnetic Resonance. <i>Revista Espanola De Cardiologia (English Ed)</i> Tj ETQq0 0 0r4BT /Overarlock 10 TF		
607	Undernourishment and Prognosis in Heart Failure. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2012, 65, 196-197.	0.4	1
608	Innovation in Cardiology: Introduction. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2013, 66, 133.	0.4	1
609	Continuing Medical Education: A Priority in <i>Revista Espa±ola de Cardiolog±a</i> . <i>Revista Espanola De Cardiologia (English Ed)</i> , 2014, 67, 1068-1073.	0.4	1
610	RF monitoring of commercial vascular stents with dipole scattering resonances. , 2014, , .		1
611	Do Inappropriate Implantable Cardioverter-defibrillator Shocks Generate Additional Costs?. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2014, 67, 65-66.	0.4	1
612	Optimal decongestive therapy in acute decompensated heart failure syndromes: Far from being solved. <i>International Journal of Cardiology</i> , 2014, 174, 457-458.	0.8	1

#	ARTICLE	IF	CITATIONS
613	2014 Annual Summary and New Projects in Revista Española de Cardiología. Revista Espanola De Cardiologia (English Ed), 2015, 68, 265-272.	0.4	1
614	Reply to the Editor "Prevalence of interatrial block during lifetime. Heart Rhythm, 2016, 13, e91.	0.3	1
615	Neprilysin Plasma Concentrations: A New Prognostic Marker in Heart Failure. Revista Espanola De Cardiologia (English Ed), 2016, 69, 535-536.	0.4	1
616	Unraveling Myocardial Mass. Journal of the American College of Cardiology, 2016, 68, 1449-1451.	1.2	1
617	Minimally invasive diagnosis of a pericardial mass by CT-guided fine-needle aspiration. Cardiovascular Pathology, 2016, 25, 275-279.	0.7	1
618	Austrian Syndrome Complicated With a Periannular Mitral Abscess. Revista Espanola De Cardiologia (English Ed), 2017, 70, 1136.	0.4	1
619	Iatrogenic pleuropericardial communication: A rare complication of percutaneous epicardial mapping. HeartRhythm Case Reports, 2017, 3, 196-198.	0.2	1
620	Risk Stratification According to Midlife Physical Fitness in an Asymptomatic Population. Journal of the American College of Cardiology, 2018, 72, 3230-3231.	1.2	1
621	Response by Nñez et al to Letter Regarding Article, "Long-Term Potassium Monitoring and Dynamics in Heart Failure and Risk of Mortality". Circulation, 2018, 138, 1613-1614.	1.6	1
622	Ex vivo assessment and in vivo validation of non-invasive stent monitoring techniques based on microwave spectrometry. Scientific Reports, 2018, 8, 14808.	1.6	1
623	No urgent need for revisiting kalaemia guidelines: rebuttal. European Journal of Heart Failure, 2018, 20, 1256-1256.	2.9	1
624	Biomarkers and heart-kidney interaction. European Heart Journal Supplements, 2018, 20, G28-G36.	0.0	1
625	A panel of multibiomarkers of inflammation, fibrosis, and catabolism is normal in healthy centenarians but has high values in young patients with myocardial infarction. Maturitas, 2018, 116, 54-58.	1.0	1
626	Left Atrial Dimension, Primary Mitral Regurgitation, and the Need of Early Surgery. Cardiology, 2019, 142, 239-241.	0.6	1
627	Targeting social disadvantage to prevent early development of heart failure. International Journal of Cardiology, 2019, 293, 181-182.	0.8	1
628	Limitación al flujo arterial en pacientes con insuficiencia cardíaca: prevalencia y factores asociados. Medicina Clínica, 2019, 153, 191-195.	0.3	1
629	An Early Post-discharge Intervention Planned to Reduce 30-day Readmissions in old and Frail Heart Failure Patients Remains Beneficial at 1 Year. Revista Espanola De Cardiologia (English Ed), 2019, 72, 261-263.	0.4	1
630	Urine: an overlooked biomedium in heart failure?. Biomarkers in Medicine, 2020, 14, 165-168.	0.6	1

#	ARTICLE	IF	CITATIONS
631	Differences in the Interleukin-1 β /Soluble ST2 Interplay Between Acute and Chronic Heart Failure. <i>Journal of Cardiovascular Translational Research</i> , 2020, 13, 864-866.	1.1	1
632	Previously Undetected Obstructive Sleep Apnea in Patients With New-Onset Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2021, 138, 46-52.	0.7	1
633	Preload dependence of pulmonary haemodynamics and right ventricular performance. <i>Clinical Research in Cardiology</i> , 2021, 110, 591-600.	1.5	1
634	Implante percutáneo de válvula en válvula por fallo de bioprótesis aórtica sin sutura: serie de casos. <i>Revista Española De Cardiología</i> , 2021, 74, 269-272.	0.6	1
635	The <sc>CONCERTâ€HF</sc> trial: a sweet and sour symphony. <i>European Journal of Heart Failure</i> , 2021, 23, 675-676.	2.9	1
636	EpCAM and microvascular obstruction in patients with STEMI: a cardiac magnetic resonance study. <i>Revista Española De Cardiología (English Ed)</i> , 2021, , .	0.4	1
637	Circulating neprilysin hypothesis: A new opportunity for sacubitril/valsartan in patients with heart failure and preserved ejection fraction?. <i>PLoS ONE</i> , 2021, 16, e0249674.	1.1	1
638	Our Journey Through Advanced Therapies to Reduce Post-Infarct Scarring. <i>Stem Cell Reviews and Reports</i> , 2021, 17, 1928-1930.	1.7	1
639	Endocarditis on a Perceval S sutureless prosthesis. A new valve with a new form of clinical presentation. <i>Revista Española De Cardiología (English Ed)</i> , 2021, 74, 635-637.	0.4	1
640	A new option for monitoring heart failure. First experience in Spain with CardioMEMS. <i>Medicina Clínica</i> , 2021, 156, 26-28.	0.3	1
641	1H-magnetic resonance spectroscopy lipoprotein profile in patients with chronic heart failure versus matched controls. <i>Revista Española De Cardiología (English Ed)</i> , 2021, , .	0.4	1
642	Iron deficiency testing and treatment in heart failure: the eyes are useless when the mind is blind. <i>European Journal of Heart Failure</i> , 2021, 23, 1855-1857.	2.9	1
643	Heart Failure Treatment by Device. <i>European Cardiology Review</i> , 2020, 15, e17.	0.7	1
644	The overlooked tsunami of systemic inflammation in post-myocardial infarction cardiogenic shock. <i>European Journal of Preventive Cardiology</i> , 2020, , .	0.8	1
645	Deep Learning Analyses to Delineate the Molecular Remodeling Process after Myocardial Infarction. <i>Cells</i> , 2021, 10, 3268.	1.8	1
646	Cardiac biomarkers retain prognostic significance in patients with heart failure and chronic obstructive pulmonary disease. <i>Journal of Cardiovascular Medicine</i> , 2021, Publish Ahead of Print, 28-36.	0.6	1
647	The epicardial delivery of cardiosphere derived cells or their extracellular vesicles is safe but of limited value in experimental infarction. <i>Scientific Reports</i> , 2021, 11, 22155.	1.6	1
648	Hospitalization following an emergency-department visit for worsening heart failure: The role of left ventricular ejection fraction. <i>Medicina Clínica</i> , 2022, 159, 157-163.	0.3	1

#	ARTICLE	IF	CITATIONS
649	Plasma NT-proBNP: a new biomarker for diagnosis and monitoring of congestive heart failure (CHF). <i>Timely Topics in Medicine Cardiovascular Diseases [electronic Resource]</i> , 2006, 10, E10.	0.1	1
650	Finding a reliable assay for soluble neprilysin. <i>Clinical Biochemistry</i> , 2022, 104, 51-58.	0.8	1
651	Circulating virome and inflammatory proteome in patients with ST-elevation myocardial infarction and primary ventricular fibrillation. <i>Scientific Reports</i> , 2022, 12, 7910.	1.6	1
652	The clinical significance of markers of coagulation in acute coronary syndromes. , 2002, , 355-364.		0
653	Predictors and Ramifications of Worsening Renal Function in Acutely Destabilized Heart Failure: Results from the ICON Study. <i>Journal of Cardiac Failure</i> , 2009, 15, S20-S21.	0.7	0
654	What Predicts Troponin Release in Acutely Decompensated Heart Failure?. <i>Journal of Cardiac Failure</i> , 2009, 15, S21.	0.7	0
655	Orthotopic Heart Transplantation in Patients With Transposition of the Great Arteries. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2009, 62, 216-219.	0.4	0
656	A New Editorial Phase With New Projects. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2010, 63, 865-868.	0.4	0
657	Telemonitorizaci3n no invasiva en pacientes con insuficiencia cardiaca y servicios de urgencias hospitalarios. Respuesta. <i>Revista Espanola De Cardiologia</i> , 2011, 64, 949.	0.6	0
658	Summary of the Clinical Studies Reported in the Annual Scientific Sessions of the American Heart Association (Chicago, United States, November 13-17, 2010). <i>Revista Espanola De Cardiologia (English Ed)</i> Tj ETQq0.0 0 rgBT/Overlock	0.4	0
659	Noninvasive Remote Telemonitoring for Ambulatory Patients With Heart Failure and Emergency Department Services. Response. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2011, 64, 949.	0.4	0
660	Summary of the Clinical Studies Reported in the European Society of Cardiology Congress 2011 (August 27-30, 2011, Paris, France). <i>Revista Espanola De Cardiologia (English Ed)</i> , 2011, 64, 1011.e1-1011.e8.	0.4	0
661	Arrhythmias: Introduction. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2012, 65, 91.	0.4	0
662	Summary of the Clinical Studies Reported in the Annual Scientific Sessions of the American Heart Association (Orlando, United States, November 12-16, 2011). <i>Revista Espanola De Cardiologia (English Ed)</i> Tj ETQq0.0 0 rgBT/Overlock	0.4	0
663	Summary of the Clinical Studies Reported in the Annual Scientific Sessions of the American College of Cardiology (Chicago, Illinois, United States, March 24-27, 2012). <i>Revista Espanola De Cardiologia (English Ed)</i> , 2012, 65, 559.e1-559.e8.	0.4	0
664	TCT-405 Transradial approach decreases in-hospital mortality in patients with cardiogenic shock. A single-center experience. <i>Journal of the American College of Cardiology</i> , 2012, 60, B116.	1.2	0
665	Letter to the Editor-“Average T-wave alternans activity in ambulatory electrocardiogram records: Commentary on the relationship with T-wave amplitude and T-wave alternans regionality. <i>Heart Rhythm</i> , 2012, 9, e6-e7.	0.3	0
666	Summary of the Clinical Studies Reported in the European Society of Cardiology Congress 2012 (August 25-29, 2012, Munich, Germany). <i>Revista Espanola De Cardiologia (English Ed)</i> , 2012, 65, 1018.e1-1018.e8.	0.4	0

#	ARTICLE	IF	CITATIONS
667	Summary of the Clinical Studies Reported in the European Society of Cardiology Congress 2013 (31 Tj ETQq1 1 0.784314 rgBT /Overlo	0.4	0
668	Self-management of Vitamin K Antagonists Is More Cost-effective Than Dabigatran for Stroke Prevention in Non-valvular Atrial Fibrillation in Spain. Revista Espanola De Cardiologia (English Ed), 2013, 66, 510-511.	0.4	0
669	Summary of the Clinical Studies Reported in the Annual Scientific Sessions of the American Heart Association (Los Angeles, CA, USA, november 3-7, 2012). Revista Espanola De Cardiologia (English Ed), 2013, 66, 55.e1-55.e11.	0.4	0
670	Analysis of Telephone Calls to a Heart Failure Unit: Reasons for the Call and Resource Use. Revista Espanola De Cardiologia (English Ed), 2013, 66, 914-915.	0.4	0
671	Summary of the Clinical Studies Reported in the Annual Scientific Sessions of the American College of Cardiology (San Francisco, CA, United States, March 8-12, 2013). Revista Espanola De Cardiologia (English Ed), 2013, 66, 482.e1-482.e8.	0.4	0
672	Pseudoatrial Fibrillation during Pacemaker Interrogation: What is the Mechanism?. PACE - Pacing and Clinical Electrophysiology, 2013, 36, 695-698.	0.5	0
673	Summary of the Clinical Studies Reported in the European Society of Cardiology Congress 2014 (August 30 â€“ September 3, 2014, Barcelona, Spain). Revista Espanola De Cardiologia (English Ed), 2014, 67, 912.e1-912.e10.	0.4	0
674	Is Cocaine-associated Acute Myocardial Infarction the Same as Myocardial Infarction Associated With Recent Cocaine Consumption?. Revista Espanola De Cardiologia (English Ed), 2014, 67, 964-965.	0.4	0
675	¿Los trastornos por cocaína asociados al infarto agudo de miocardio son lo mismo que el infarto de miocardio asociado al consumo reciente de cocaína?. Revista Espanola De Cardiologia, 2014, 67, 964-965.	0.6	0
676	Comments on the Analysis of Telephone Calls to a Heart Failure Unit: Reasons for the Call and Resource Use. Response. Revista Espanola De Cardiologia (English Ed), 2014, 67, 158-159.	0.4	0
677	Resumen de los ensayos clínicos presentados en las Sesiones Científicas Anuales de la American Heart Association (Chicago, Illinois, Estados Unidos, 15â€“19 de noviembre de 2014)1. Revista Espanola De Cardiologia, 2015, 68, 145.e1-145.e8.	0.6	0
678	To the Editorâ€” Interatrial block: Another risk to take into account after radiofrequency ablation of typical atrial flutter. Heart Rhythm, 2015, 12, e119-e120.	0.3	0
679	Summary of the Clinical Studies Reported in the Annual Scientific Sessions of the American Heart Association (Chicago, Illinois, United States, November 15-19, 2014). Revista Espanola De Cardiologia (English Ed), 2015, 68, 145.e1-145.e8.	0.4	0
680	Fate of Original Articles Rejected by Revista Espanola de Cardiologia. Revista Espanola De Cardiologia (English Ed), 2015, 68, 263-264.	0.4	0
681	Acute Heart Failure: The Unrecognized Epidemic. Revista Espanola De Cardiologia (English Ed), 2015, 68, 243-244.	0.4	0
682	Morbidity and mortality in systolic heart failure also associated with raised serum neprilysin levels. Reply. International Journal of Cardiology, 2015, 190, 201.	0.8	0
683	Answer. Reverse remodeling in systolic heart failure. The ST2-R2 score: a puzzle yet to be solved?. International Journal of Cardiology, 2015, 187, 556.	0.8	0
684	Impassable brachiocephalic tortuosity in right transradial access: Overcoming the curves with the pigtail catheter. International Journal of Cardiology, 2015, 180, 76-77.	0.8	0

#	ARTICLE	IF	CITATIONS
685	Equalization of Intracardiac Pressures in Cardiac Tamponade. <i>Anesthesia and Analgesia</i> , 2016, 122, 959-962.	1.1	0
686	What is on the horizon for improved treatments for acutely decompensated heart failure?. <i>European Heart Journal Supplements</i> , 2016, 18, G33-G42.	0.0	0
687	Biomarkers in Heart Failure: ST2. , 2016, , 251-268.		0
688	ST2-Based Precision Medicine in Device Management: the Next Frontier Beyond MADIT-CRT?. <i>Journal of Cardiovascular Translational Research</i> , 2016, 9, 419-420.	1.1	0
689	RAS Fingerprint. <i>Journal of the American College of Cardiology</i> , 2017, 69, 3010-3011.	1.2	0
690	Reply. <i>European Journal of Heart Failure</i> , 2017, 19, 1736-1736.	2.9	0
691	Idiopathic Dilated Cardiomyopathy: Molecular Basis and Distilling Complexity to Advance. , 0, , .		0
692	Metabolic effects of sacubitril/valsartan: are they relevant in clinical practice?. <i>Cardiovascular Diagnosis and Therapy</i> , 2018, 8, 549-551.	0.7	0
693	Letter by Fung et al Regarding Article, "Frailty and Clinical Outcomes in Heart Failure: A Systematic Review and Meta-analysis". <i>Journal of the American Medical Association</i> , 2018, 19, 1143-1146.	1.2	0
694	Evolutionary echocardiographic changes in cardiac amyloidosis: Look at the whole picture. <i>Echocardiography</i> , 2018, 35, 1042-1044.	0.3	0
695	Reply. <i>Journal of the American College of Cardiology</i> , 2019, 74, 479-480.	1.2	0
696	Airflow limitation in patients with heart failure: Prevalence and associated factors. <i>Medicina Clínica (English Edition)</i> , 2019, 153, 191-195.	0.1	0
697	Distal Bioresorbable Vascular Scaffold Strut Embolization Detected at Late Follow-Up. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, e63-e65.	1.1	0
698	Efficacy and safety of combined neprilysin and RAS inhibition in heart failure: Let's leave the doubts behind. <i>International Journal of Cardiology</i> , 2020, 300, 198-200.	0.8	0
699	Circulating Marine and Vegetable Omega-3 at the Time of ST-Segment Elevation Myocardial Infarction and Incident Hard Clinical Endpoints. <i>Current Developments in Nutrition</i> , 2020, 4, nzaa061_111.	0.1	0
700	Identifying very low-risk STEMI patients for early ICU discharge in the COVID-19 era. <i>Clinical Research in Cardiology</i> , 2020, 109, 1582-1584.	1.5	0
701	Highly sensitive troponin T dynamics and prognosis in asymptomatic severe aortic stenosis. <i>Revista Española De Cardiología (English Ed)</i> , 2020, 73, 1065-1066.	0.4	0
702	Response. The ST2-SCD score in ambulatory heart failure patients. <i>International Journal of Cardiology</i> , 2020, 300, 207.	0.8	0

#	ARTICLE	IF	CITATIONS
703	Implicaciones clínicas del bloqueo interauricular avanzado: síndrome de Bayés. Medicina Clínica, 2021, 156, 233-234.	0.3	0
704	Neprilysin Inhibitors. , 2021, , 1-8.		0
705	Reply. Journal of the American College of Cardiology, 2021, 77, 1026-1028.	1.2	0
706	Clinical implications of advanced interatrial block: Bayés syndrome. Medicina Clínica (English) 101(10):50-56, 2021.	0.1	0
707	Professor Bernard Lown. Journal of the American College of Cardiology, 2021, 77, 1689-1690.	1.2	0
708	Reply. JACC: Heart Failure, 2021, 9, 407-408.	1.9	0
709	Endocarditis sobre prótesis sin sutura Perceval S. Una nueva válvula con una nueva forma de presentación clínica. Revista Española De Cardiología, 2021, 74, 635-637.	0.6	0
710	Atrioventricular Node Ablation to Enhance Resynchronization Therapy Response in a Patient With Complete Atrioventricular Block. JACC: Case Reports, 2021, 3, 150-155.	0.3	0
711	A new option for monitoring heart failure. First experience in Spain with CardioMEMS. Medicina Clínica (English Edition), 2021, 156, 26-28.	0.1	0
712	Acute Coronary Syndromes in 2011 and 2012. Arquivos Brasileiros De Cardiologia, 2013, 101, 473.	0.3	0
713	Left Ventricular Ejection Fraction in Heart Failure. European Cardiology Review, 2018, 13, 91.	0.7	0
714	Repeat physical stress echocardiography in asymptomatic severe aortic stenosis. Cardiology Journal, 2020, 27, 307-308.	0.5	0
715	Dinámica de troponina T de alta sensibilidad y pronóstico en pacientes con estenosis aórtica grave asintomática. Revista Española De Cardiología, 2020, 73, 1065-1066.	0.6	0
716	Neprilysin Inhibitors. , 2021, , 1075-1082.		0
717	Perfil lipoproteico por espectroscopia nuclear magnética en pacientes con insuficiencia cardíaca crónica comparado con controles apareados. Revista Española De Cardiología, 2022, , .	0.6	0
718	CardioPulse: additional history on myocardial infarction, from the seventeenth century to the present. European Heart Journal, 2013, 34, 1614.	1.0	0
719	Commentary: A Review of Prognosis Model Associated With Cardiogenic Shock After Acute Myocardial Infarction. Frontiers in Cardiovascular Medicine, 2022, 9, 856592.	1.1	0
720	Response by Vilalta et al to Letter Regarding Article, "Midterm Outcomes Following Sutureless and Transcatheter Aortic Valve Replacement in Low-Risk Patients With Aortic Stenosis". Circulation: Cardiovascular Interventions, 2022, 15, CIRCINTERVENTIONS122011850.	1.4	0

#	ARTICLE	IF	CITATIONS
721	Translational proteomics in cardiogenic shock: from benchmark to bedside.. Journal of Geriatric Cardiology, 2022, 19, 158-162.	0.2	0
722	Incidence, Treatment and Clinical Impact of Iron Deficiency in Chronic Heart Failure: A Longitudinal Analysis. Journal of Clinical Medicine, 2022, 11, 2559.	1.0	0
723	La ecografía pulmonar en el seguimiento de la congestión pulmonar subclínica de pacientes ambulatorios con insuficiencia cardiaca. Revista Espanola De Cardiologia (English Ed), 2022, , .	0.4	0
724	Potential role of empagliflozin in myocardial iron repletion following ferric carboxymaltose for heart failure. Revista Espanola De Cardiologia (English Ed), 2023, 76, 121-123.	0.4	0
725	The Potential Anti-remodeling Effect of Paroxetine After Myocardial Infarction May Be Blunted by Beta-Blockers. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	0